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Abstract 
Background 
Cystic fibrosis transmembrane conductance regulator (CFTR) modulating drugs called 
correctors aim to provide treatment for people with cystic fibrosis (CF) who have F508del 
variants in their CFTR gene. Novel correctors are currently being tested both in 
monotherapy, and in combination with other CFTR modulators, new trials need 
incorporating into systematic reviews and meta-analyses. 
New therapies are tested in preschool children with CF (pscwCF); there is currently no 
agreed core outcome set for this group and it is unknown if measured outcomes are 
providing the most meaningful information for all stakeholders. We studied outcomes in 
this age group as the start of a process to develop a core outcome set (COS). 
Methods 
Cochrane review- An update of the Cochrane systematic review on correctors was 
performed. A comprehensive search of the Cochrane Cystic Fibrosis and Genetic Disorder 
Cystic Fibrosis Trials Register and eligibility assessment identified new parallel RCTs to 
include. Data on relevant outcomes was extracted and input into meta-analyses. 
Review of outcomes- Cochrane systematic reviews including trials with pscwCF as 
participants were identified. From those reviews, we identified trials exclusively enrolling 
preschool children with CF. We found the protocols for each review and trial, where 
available. Outcomes stated in the protocol, methods and results for each review and trial 
were extracted and categorised into a group of themes reflecting treatment aspects of CF 
(airway, microbiology, extra-thoracic manifestation, patient/parent reported, nutrition, 
other- to include outcomes which don’t fall under any of these themes).  
Results 
Cochrane review- 4 new trials were identified. 1 phase one examining a corrector in 
monotherapy and 1 phase one plus 2 phase two trials examining triple combination therapy 
(VX-659 or VX-445-tezacaftor-ivacaftor). At four weeks, pooled results for F508del/MF 
participants for triple combination regimens improved the CFQ-R respiratory domain versus 
placebo (MD 12.03 points (95% CI 8.36 to 15.71)). For relative change in FEV1, triple 
combination saw an improvement vs. placebo (MD: 22.78% [95% CI: 18.92, 26.63]. The 
mean difference for absolute change in FEV1 showed an improvement of 0.47 Litres [95% 
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CI: 0.40, 0.55] compared to placebo. Pooled absolute change in sweat chloride showed 
triple combination therapy led to a decrease compared to placebo (MD: -39.34 [95% CI: -
43.04, -35.65]). Similar improvements were seen for participants with the F508del/F508del 
genotype. There was no statistically significant difference in adverse events and their 
severity between intervention and placebo groups in either genotype. There was no 
statistically significant difference in pulmonary exacerbation rates observed across the 
pooled results or between genotypes. All three of the triple combination studies were 
judged to have a moderate to high quality evidence. 
Review of outcomes- We identified 29 eligible Cochrane systematic reviews which 
contained 295 trials, 10 of which were eligible for inclusion. For 6/10 trials, risk of bias was 
high (unclear in 3/10, low in 1/10). In the results sections of the trials, 65 different 
outcomes were reported 127 different times. The most common treatment related themes 
were other (outcomes which do not fit under other predefined themes, n=19) and airway 
(n=17). Least common treatment related theme was patient/parent reported (n=3). 
Discussion 
Cochrane review- There is insufficient evidence that monotherapy with correctors has 
clinically important effects in people with CF who have two copies of the F508del variant. 
Triple combination therapies (VX-445-tezacaftor-ivacaftor or VX-659-tezacaftor-ivacaftor), 
showed improvements in clinical outcomes for people with CF. At this stage, no significant 
safety concerns were identified, this will be further monitored with the emergence of 
longer-term data. 
Review of outcomes- Despite a wide search, only ten eligible trials were found, six with a 
high risk of bias. A large number of different outcomes were measured, with the majority 
being surrogate biomarkers. There was a lack of pragmatic, longer term outcomes which 
give information about the lived experience of preschool children with CF and their 
families. Preschool years are vital for the future health of people with CF. A clear core 
outcome set would facilitate high quality research in preschool children with CF. 
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Aims of this work 
• Update Cochrane systematic review- Safety and efficacy of CFTR correctors for class 
II mutations (variants). 
• Produce an up to date, systematic evaluation of outcomes reported in trials 
including pre-school children. 
 
Variant nomenclature 
The term “variant” is used throughout this dissertation as mutation is no longer considered 
an acceptable term.  The first time a variant is described, it will be named using the Human 
Genome Variation Society (HGVS) nomenclature with the legacy name in brackets, for 
example c.1521_1523delCTT (F508del). Thereafter the legacy name will be used. 
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1. Introduction 
Throughout medical school, I have found cystic fibrosis (CF) an interesting field concerning 
a variety of issues from the initial genetic defect to multi-system pathophysiology and novel 
high cost drugs. When I learnt about CFTR modulating drugs, I found them particularly 
fascinating. I had very basic experience of conducting a systematic review and wanted to 
build upon this to form important skills for an evidence-based practitioner and researcher 
of the future. I spent time with the CF team at Alder Hey and found there was an 
opportunity to combine these interests with the development of these skills and 
experience, as well as to contribute towards work that makes a difference to people with 
CF and their families. When undertaking this review, I found there a lack of guidance on the 
best, or most valuable outcomes for trials to measure in pre-school children with CF 
(pscwCF) and decided to pursue this further with the aim of laying the foundation for future 
work to improve the quality of research in pscwCF by developing a core outcome set for 
this population. 
1.1 What is Cystic Fibrosis? 
In people of Northern European descent, CF is the most common life-shortening genetic 
disease. 1 in 2000 Northern Europeans are born with cystic fibrosis (1). A genetic defect in 
the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leads to non-
formation, or formation of a poorly or non-functioning CFTR transmembrane protein, which 
is typically found in cells at all epithelial surfaces throughout the body. This leads to 
abnormal salt transport (chloride, bicarbonate and anions) and deranged movement of 
water across membranes. In the lungs this leads to a decreased volume of airway surface 
liquid with impact on airway clearance through the mucociliary escalator. Decreased 
mucociliary clearance leads to a greater vulnerability to infections. Recurrent or chronic 
infection leads to chronic inflammation and progressive damage to the airways which 
eventually leads to respiratory failure. Abnormal ion transport in the pancreas leads to a 
fibrocystic pathology that impacts on exocrine and endocrine function with frequent 
malabsorption of products of digestion and sometimes diabetes mellitus. Excess loss of salt 
in sweat can lead to salt depletion. Other problems are described later. 
CF affects approximately seventy thousand people around the world and is more common 
in people with ancestry from Northern Europe (2). In fact, a gradient of incidence is 
observed from the highest in the northwest to lowest in the southeast of Europe, reflecting 
a likely migration pattern of ancient civilisations from northern areas who spread across 
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Europe, carrying some of the first cystic fibrosis alleles with them. A recent paper suggests 
that it may have been those who spread their pottery skills across Europe (known as the 
Bell Beaker culture) who first carried CF across an entire continent (3). Currently, cystic 
fibrosis invariably leads to the shortening of a person’s life. The Cystic Fibrosis Trust’s (a UK 
charity dedicated to support those living with CF and their families, as well as promote 
research into its treatment) most recent annual data report found median survival of a 
person with CF in the UK to be forty seven years (4). According to the US National Institute 
of Health (NIH), Respiratory failure is the most common cause of death in people with CF 
(5). The Cystic Fibrosis Foundation (a US based non-profit organisation) registry in 2006 
found 90% of reported deaths were cardiorespiratory failure (6), whereas the 2016 report 
found 67% to be due to the same cause (7).  
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1989 
CFTR gene 
identified and 
characterised as 
the genetic cause 
of cystic fibrosis. 
2007- 
newborn 
screening for 
CF introduced 
for all children 
across the UK. 
1993  
Dornase alfa, a 
mucolytic, is 
approved for use 
by the FDA. 
1997 
Inhaled tobramycin is 
approved for use by the 
FDA. Although nebulised 
colistin had been in use 
as standard of care in 
Europe for 
approximately 20 years. 
2006 
The first CFTR 
modulator, the 
potentiator ivacaftor, 
begins clinical trials.  
 
2015 
Lumacaftor, the first 
drug marketed as a 
corrector is approved 
is approved for use in 
combination with 
ivacaftor by the FDA. 
2018 
Tezacaftor, the 
second drug 
marketed as a 
corrector, is 
approved for use 
by the FDA. 
2019 
In the 30th anniversary 
year of discovery of the 
CFTR gene, next 
generation elexacaftor 
is submitted for   
universal regulatory 
approval. 
Figure 1: Timeline describing milestones in treatment of CF following discovery and characterisation of the CFTR gene as the 
cause of CF. 
1991 
Characterisation of CFTR as a 
chloride channel 
2012 
Ivacaftor approved by the 
FDA. 
1989 
2019 
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1.2 Newborn screening 
Newborn bloodspot screening for CF using the heel prick bloodspot card was introduced 
across the whole of the UK in 2007, but it had also been growing in availability around the 
country before this after the Cystic Fibrosis trust launched a campaign in 1996, when 80% 
of newborns were not screened for CF (10). In 2017, at the 10 year anniversary of the 
national screening programme, over six million newborns had been screened and almost 
3,000 diagnoses of CF were made as a direct result of screening (10). Newborn screening 
leads to an earlier diagnosis than previous symptom-based diagnoses and therefore allows 
earlier intervention. There is also evidence that screening can lead to greater 
improvements in anthropometric measures of nutrition as an infant, through to benefitting 
survival rates as an adult with CF (11, 12).  
 
1.3 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variants 
The aetiology of CF stems from the inheritance of two CF causing variants in the CFTR gene, 
one from each parent. These variants lead to errors at different points along the processing 
pathway through which CFTR is synthesised. Over 1900 variants have been described and 
over 1500 of these are known to cause CF (13). The point on the CFTR processing pathway 
which a variant disrupts determines the classification of the variant. 
1.3.1 Classification of CFTR variants 
The different classes of CFTR variant are (13, 14): 
• Class 1- No CFTR synthesis. Can occur due to frameshifts leading to premature stop 
codons and nonsense sequences, leading to degradation of mRNA before 
translation of the protein. Examples of this mutation include c.3846G>A (W1282X), 
c.1657C>T (R553X), and c.1624G>T (G542X). 
• Class 2- Misfolded CFTR. Variants which can lead to an incorrectly folded CFTR, 
which is recognised as abnormal, retained in the endoplasmic reticulum and broken 
down before being transported to the cell surface membrane. Examples include 
c.1521_1523delCTT (F508del) (the most common mutation (13)) and c.3909C>G 
(N1303K). 
• Class 3- Gating defect. Trafficking to the cell surface is successful in this class. CFTR 
channel is either closed or shows decreased opening. Can occur due to missense 
10 
 
mutations which disrupt how CFTR is affected by its usual regulatory factors. 
Examples: c.1652G>A (G551D), c.1651G>A (G551S). 
• Class 4- Conductance defect. Trafficking to the cell surface is successful in this class. 
Missense mutations alter the shape of the channel, making it more difficult for 
chloride and bicarbonate ions to pass through. Examples: c.350G>A (R117H), 
c.1000C>T (R334W), c.1040G>C (R347P). 
• Class 5- Decreased number of CFTR channels. variants leading to alternative 
splicing, disrupting mRNA which results in formation of both non-functional CFTR 
and a small number of functional channels at the surface membrane. Example: 
c.3140-26A>G (3272-26A-->G). 
• Class 6- CFTR is functional but quickly removed from cell surface and broken down. 
Occurs as a result of variants that cause CFTR to be less stable when at the cell 
surface by increasing endocytosis of CFTR or decreasing its recycling back to the cell 
surface. Example: c.4197_4198delCT (4326delTC) (14). 
• Some have suggested the formation of a seventh class of variant- “Unrescuable” 
variants, for example large deletions, which are unable to be rescued by current 
pharmacological strategies (14). Existence of this class has not yet been universally 
accepted. 
 
It is useful to consider that classes 1, 2, 5, 6 (& 7) affect the quantity of functional 
CFTR at the cell surface membrane, whereas classes 3 & 4 affect the quality at 
which the CFTR functions when at the surface (see Figure 1 below) (15, 16). 
Variants are sometimes described as minimal function (class I & II), where little or 
no functional CFTR is synthesised, or residual function (class IV-VI), where a small 
amount of functional CFTR reaches the cell surface. Class III variants are referred to 
as gating variants due to their likely response to potentiators (16). 
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Figure 2: Relating the different types of variant to how it affects CFTR and what it means for its function. Used 
with permission from ‘The increasing challenge of genetic counselling for cystic fibrosis’ by Foil KE et al. Journal 
of Cystic Fibrosis, March 2019 (16). 
 
1.4 Treatment strategy 
1.4.1 Relating treatment to pathophysiology 
As mentioned above, due to CFTR being present on many epithelial surfaces around the 
body, the underlying defect in CF leads to numerous problems, making CF a multi-system 
disease. Notable manifestations of CF include the accumulation of, and difficulty in clearing 
highly viscous secretions in the airways, leading to increased vulnerability to respiratory 
tract infection, chronic inflammation leading to progressive airway damage and eventual 
respiratory failure.  
CF can also lead to ineffective clearance of digestive enzymes from pancreatic ducts, 
leading to pancreatic damage and insufficiency. This inadequate release of digestive 
enzymes into the gastrointestinal tract causes decreased absorption of nutrients from the 
products of digestion meaning that people with CF can be malnourished and children may 
experience failure to thrive (17). It is considered a spectrum of severity, with the severity 
being influenced by the CFTR genotype combination which the person with CF possesses 
(18, 19). The CF Foundation’s 2017 patient registry report states that as of its data 
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collection period, 85.7% of people on the registry were taking pancreatic enzyme 
replacement (7). 
A further possible consequence of pancreatic damage and possible insufficiency is 
development of cystic fibrosis related diabetes mellitus (CFRD). The pathophysiology of this 
is multifactorial but a key component to note is the build-up of thick mucus in the 
pancreatic ducts causing obstructions which lead to inflammation and progressive damage 
to the pancreas, including its insulin-producing β cells- meaning the insulin producing 
capabilities of the pancreas are decreased; sometimes to the point where a person with CF 
is unable to adequately regulate their blood sugar levels (20-23). People with CF can also 
show decreased sensitivity to insulin due to the presence of infection and/or inflammation 
in the body plus the possible use of corticosteroids as part of their treatment (23). The 2017 
UK CF registry report states that 29.8% of people aged over 10 years with CF in the UK were 
taking treatment for CFRD  and an American study showed that the proportion of people 
with CF who were diagnosed with CFRD increased with age (24).  
People with CF are at increased risk of developing low bone mineral density due to several 
risk factors including: reduced absorption of vitamin D and calcium, use of corticosteroids, 
potential for decreased physical exercise and possible hypogonadism (25, 26). Low bone 
mineral density becomes more common in people with CF as they get older, as well as with 
increasing severity of lung disease and malnutrition (26, 27). 
It is a common occurrence in CF for bile ducts to become blocked, leading to inflammation, 
damage and eventually failure of the liver. Liver disease is the second most common cause 
of death in CF after lung disease, and accounts for 2-4% of deaths in those with CF (28-30). 
The most common disease process occurring in the bowel of people with CF is obstruction 
(meconium ileus if present in a neonate, or distal intestinal obstruction syndrome). This 
occurs due to the disrupted regulation of salt & water in the lumen of the bowel leading to 
build up of extremely viscous meconium or stool. 
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1.4.2 Treating children with CF 
Children with CF, especially pscwCF, are likely to have minimal lung disease in most cases 
and approaches to management are pro-active and preventative.  
There are three principle treatment goals for children with CF: 
• Maintenance of excellent nutrition 
• Keeping the airway clear of infection 
• Staying active & healthy 
1.4.3 Universal/non-variant specific therapies 
The treatments discussed in this section could be regarded as maintenance therapies to 
keep the person well, or reactive therapies to help the person get better or more stable 
following a deterioration of their health. They are independent of the different CFTR 
variants a person with CF may have, and are applicable to all people with CF. 
Treatment also varies between the everyday maintenance therapies for a person with CF 
who is currently well, compared to when they develop acute problems. As the work 
discussed in this thesis focusses on regular treatments taken every day and not intended to 
address an acute problem, but more rather to prevent acute problems; we will briefly 
discuss the components of everyday CF management which are the cornerstones of 
keeping a person with CF as well as possible. Cystic fibrosis is an example of a condition 
where multidisciplinary input is of vital importance. 
As we know, cystic fibrosis affects multiple different systems of the body in multiple 
different ways. It is important to address as many of these ways as possible in order to halt 
or slow progression of damage to the body’s multiple affected systems. In children, this can 
be centred around the 3 main treatment goals above. 
1.4.4 Excellent nutrition 
CF specialist dietitians who support the optimum balance of nutrition and encourage intake 
of nutritious high energy foods as part of a healthy lifestyle (31). Cochrane systematic 
reviews of this area acknowledge the importance of optimal nutrition, yet also identify 
there is often a lack of high quality evidence for the optimum use of the interventions 
which they cover, which is not comprehensive (32-38). 
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1.4.4.1 Pancreatic enzyme replacement therapy & vitamin supplementation 
Pancreatic enzyme insufficiency occurs when the exocrine pancreas is unable to produce 
and/or release adequate amounts of digestive enzymes into the digestive tract for 
digestion and absorption (17). Enzyme replacement aids with the breakdown & absorption 
of fats, proteins and carbohydrates. In addition, people with CF will also take supplements 
of the fat-soluble vitamins (A, D, E, and K) where required. Proton pump inhibitors or 
Histamine-2 receptor antagonists are often prescribed to make stomach chyme less acidic 
and aid the function of the enzymes. This also can improve the symptoms of gastro-
oesophageal reflux that people with CF can experience (39, 40).  
1.4.4.2 Hepatic disease 
The mainstay of treating hepatobiliary complications in CF is to supplement bile acids in the 
form of ursodeoxycholic acid (41). Liver transplant is considered for profound portal 
hypertension or in rare cases, hepatic failure. 
1.4.4.3 Intestinal disease 
Meconium ileus or distal intestinal obstruction syndromes can occur due to stool that 
requires softening and removing by a combination of laxatives, intravenous fluids, N-
acetylcysteine, pancreatic supplements and gastrograffin (39, 42). In severe cases, usually if 
the bowel is completely obstructed, surgery may be indicated. In some cases a colonoscopy 
may be an alternative to surgery (42). 
1.4.4.4 CFRD 
There is no clear consensus on the best approach to identify and manage CFRD. Typical 
treatment for CFRD is with insulin (23, 43). 
1.4.4.5 CF related bone disease 
Low bone mineral density- Options for treatment include vitamin D and calcium 
supplements and bisphosphonates. Some literature mentions the use of sex steroid 
replacement and supplement of anabolic agents such as parathyroid hormone or growth 
hormone, but less evidence is available for these and their use is less widespread (26). A 
Cochrane review examining bisphosphonates in CF shows them to be effective in increasing 
bone mineral density; their adverse effects  are also important to be considered and 
monitored for (44). These range from nausea & vomiting, to oesophagitis, renal toxicity and 
jaw osteonecrosis. 
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1.4.4.6 Salt regulation 
People with CF have impaired regulation of salt and water. This means they lose a higher 
amount of salt in their sweat. This salt needs replacing through supplementation (40). 
1.4.5 Keeping airways clean 
Respiratory disease is the most common cause of morbidity and mortality in CF (39). The 
main aims are to clear thick secretions from airways and promptly treat any respiratory 
infection (45). 
1.4.5.1 Airway clearance: 
 The aim of this is to loosen secretions into the airway lumen to allow them to be coughed 
up. Before prescribing medications, it is important to involve CF specialist physiotherapists 
who can perform and teach manual airway clearance techniques, including postural 
drainage and the active cycle of breathing technique (46, 47). A Cochrane systematic review 
found that chest physiotherapy leads to clearance of more airway secretions compared to 
no chest physiotherapy (48). Physiotherapists can also encourage exercise which is vitally 
important for mucus clearance and aerobic health, and also provide expert input around 
devices which may prove useful, such as ‘flutter valves’ and oscillating vests (49). Short 
acting bronchodilators may also be given to aid the process of airway clearance (39). There 
are many Cochrane systematic reviews of physiotherapy interventions to aid airway 
clearance and aerobic health, with many highlighting its value. They also state that there is 
little evidence to show one technique to be superior in clearing airway secretions to others, 
and that airway clearance methods should account for what is most effective and fits with 
the preferences of the individual with CF. This is supported by the findings of a Cochrane 
meta-systematic review which combined the findings of other Cochrane systematic reviews 
(46, 50-53). Although one review did find positive airway pressure physiotherapy to lead to 
a lower rate of pulmonary exacerbations (54).  
1.4.5.2 Antimicrobial prevention & therapy:  
Prevention of infection is important and the Cystic Fibrosis Foundation (CFF) recommend 
guidelines for infection prevention and control, they include: clinicians using contact 
precautions e.g. gloves & aprons, separating people with CF by at least 6 feet to avoid 
droplet transmission, hand washing for the person with CF and their close contacts and 
clinicians. The guidelines also recommend people with CF can wear surgical face masks 
when in a healthcare environment (55). As well as such precautions, people with CF should 
receive all routine vaccinations, including influenza and pneumococcal vaccines (56, 57). 
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Currently, guidelines state there is insufficient and conflicting evidence to support the use 
of palivizumab to prevent infection with respiratory syncytial virus in young children with 
CF (57-61). Further important methods of prevention are to perform routine respiratory 
cultures and for clinicians to have a low threshold to perform bronchoscopy & take 
samples. 
Pseudomonas aeruginosa is an important pathogen in CF as it is linked with a more rapid 
deterioration in the lung function of people with CF. It is typically not recommended to take 
continuous prophylactic antibiotics against pseudomonas as multiple trials have shown 
there to be no overall benefit to people with CF (45, 62-64). NICE (National institute for 
health & care excellence), the UK body who use evidence-based approaches to determine 
best practice guidelines and advise the UK government on commissioning therapies, also 
does not recommend prophylactic antibiotics against other clinically significant pathogens 
in adults with CF who are currently well. NICE do however recommend prophylaxis against 
respiratory Staphylococcus aureus in children up to the age  of three years, and consider 
continuing its use up to six years of age (31). Antibiotics can be very useful in efforts to 
eradicate bacterial infections and to prevent them becoming a chronic infection, with early 
identification and treatment being paramount, hence the importance of routine cultures 
and low threshold for bronchoscopy (39, 65). As a result of its negative effects on 
pulmonary function Pseudomonas is an example of a pathogen which should be targeted 
for eradication. There is however uncertainty as to the best approaches toward eradication 
therapy; the TORPEDO-CF study (awaiting publication at time of writing) found there to be 
no significant difference between intravenous ceftazidime and tobramycin combination 
antibiotic therapy versus oral ciprofloxacin in the eradication of early infection of 
Pseudomonas aeruginosa in people with cystic fibrosis (66). 
1.4.5.3 Mucolytic therapy:  
This aims to assist with airway clearance by making the secretions less viscous. There are 
multiple inhaled agents including an enzyme which breaks down DNA in inflammatory cells 
in the airway (Dornase alfa). A Cochrane review found that dornase alfa can be taken at a 
time near to airway clearance techniques that is preferred by the individual (67). Osmotic 
agents draw water into the secretions (mannitol). A Cochrane review examining inhaled 
mannitol in people with CF found it to improve pulmonary function, but not quality of life 
versus control (although this was based on low quality evidence) (68). Finally some agents 
work by multiple mechanisms of action such as osmotic action, disrupting ionic bonds and 
dissociating DNA in the secretions to facilitate proteolysis (hypertonic saline) (39, 69). A 
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Cochrane review found nebulised hypertonic saline to lead to improvements in pulmonary 
function, and an RCT found it to lead to statistically significantly lower occurrence of 
pulmonary exacerbations versus control (see figure 3 below) (67, 70). Another Cochrane 
review recommends inhaling hypertonic saline twice a day and states that despite there not 
being a difference in measured pulmonary function, taking it before or during airway 
clearance techniques leads to a greater feeling of satisfaction compared to inhaling it after 
these techniques (71). A recent multicentre randomised placebo-controlled trial (Inhaled 
hypertonic saline in preschool children with cystic fibrosis (SHIP)) found hypertonic saline to 
be safe and to lead to a statistically significant decrease in LCI2.5  (the number of times an 
individual’s total lung volume will pass through their lungs for the concentration of a tracer 
gas to reach 2.5% of its concentration at the start of the test) versus isotonic saline placebo 
(mean treatment effect -0.63 LCI2.5 units, 95% CI -1.10 to -0.15, p=0.010) in children aged 3-
6 years (72). This suggests that inhaled hypertonic saline could be offered routinely to 
young children as part of their treatment, but an important consideration made in a 
comment on this trial states that the extra treatment burden of this extra intervention 
should also be considered (73). 
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Figure 3: Kaplan-Meier survival plots showing inhaled hypertonic saline leads to significantly less pulmonary 
exacerbations at given time points. From Elkins et al. NEJM 2006 (70). 
Kaplan-Meier survival plots show the number and rate of occurrence of events, in this case 
pulmonary exacerbation. Each time a person suffers a pulmonary exacerbation. The line for 
their group (intervention or placebo) moves down. In Figure 3 we can see that hypertonic 
saline led to a less people having a pulmonary exacerbation versus placebo at any given 
time point (70).  
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1.4.5.4 Airway inflammation: 
 Inflammatory processes in CF airways are dominated by neutrophils. This chronic state of 
inflammation has been shown to be damaging to the airways (74). There are multiple 
pharmacological approaches to reduce inflammation in the airways. Notably anti-
inflammatory agents such as corticosteroids and non-steroidal anti-inflammatory drugs 
(NSAIDs) have been shown to be effective at reducing inflammation, however it is 
important to consider their known adverse events (39, 65, 75-79). A Cochrane systematic 
review found long term oral corticosteroids to slow progression of lung disease, but noted 
the significance of adverse events, suggesting a risk-balance analysis of alternate day low-
dose regimens may be useful (80). The Cochrane review examining NSAIDs in cystic fibrosis 
has shown high-dose ibuprofen to slow progression of lung disease (75). 
1.4.6 Staying active & healthy 
It is important for people with CF to exercise for numerous reasons. Exercise helps maintain 
lung function and improve airway clearance (81). Through improved exercise tolerance it 
can help against shortness of breath (82). Exercise can also potentially help manage CFRD 
through improving sensitivity to insulin and decreasing systemic inflammation (83). 
Additionally exercise can also maintain bone mineral density (84), as well as potentially 
help decrease levels of anxiety & depression (85). Another benefit of using exercise as an 
intervention is that it typically has very little, if any adverse events. A Cochrane review 
examining this intervention says that further work would be useful to determine the 
optimum balance of a combination of aerobic and anaerobic exercise in CF (86). 
1.4.7 CF and fertility 
Women with cystic fibrosis are able to become pregnant but may find it more difficult to 
conceive due to a poorer nutritional status and/or thicker cervical mucus (87). Around 98% 
of males with CF have congenital bilateral absence of the vas deferens but cystic fibrosis 
would not typically cause a problem with the sperm itself, meaning sperm can still be 
extracted and used to conceive by means such as in vitro fertilisation (88). 
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1.5 Therapies which address the underlying defect 
The components mentioned above have formed the main pillars of CF treatment for a long 
time and contribute to a significant treatment burden. In the past 10 years, a new approach 
has emerged: using small molecule drugs which directly target the underlying defect in the 
CFTR.  
1.5.1 Potentiators 
An example of a potentiator is ivacaftor, a medication taken orally twice a day. Potentiators 
help improve the function of the CFTR protein at the cell membrane by increasing the 
probability that a CFTR channel will be open at a given point in time, meaning it can be used 
independently (as monotherapy) in people with CF who have class III or IV variants in their 
CFTR, which has already made it to the cell surface (89). This intervention has remarkable 
impact for people with CF who have the G551D and other class III CFTR variants (90, 91). 
The findings were so profound that the effects of ivacaftor for those with applicable class III 
and IV variants are now considered the benchmark against which other variant specific 
therapies should be compared.  
1.5.2 Correctors 
Though effective for the above classes of variants, there is no evidence to suggest ivacaftor 
alone provides benefit to those with the F508del variant (91). This is to be expected, as 
ivacaftor requires CFTR to be present at the cell surface membrane in order to potentiate 
its opening. This means that ivacaftor alone is not a suitable therapy for the large 
proportion of people with CF who don’t have a class III or IV variant. 
In class II variants where there is a problem with folding of the CFTR before it reaches the 
cell surface, the folding must first be corrected to reach the cell surface. Before F508del 
variant specific drugs were synthesised, it was demonstrated in 1997 that the folding & 
trafficking defect of the class II F508del variant can be corrected by lowering the 
temperature of the cell. It was shown that by incubating CFTR proteins with the F508del 
trafficking defect at 26 degrees Celsius for 2 days led to formation of folded, functional 
CFTR channels (92). This served to show that it was possible to overcome the defects in 
folding and trafficking to the surface and formed the basis of work into possible therapies 
to help correct the F508del variant of the CFTR protein. 
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Medications such as lumacaftor and tezacaftor are known as correctors. Correctors aim to 
address class II variants, including F508del. Approximately 80-90% of people with CF have 
at least one copy of a class II variant with 70% of people with CF from European descent 
specifically having F508del (13). Correctors aim to mask the abnormal folding of the CFTR 
protein, which is defective in the presence of F508del (89). This allows the CFTR to reach 
the cell surface membrane, restoring the transport of salts (93-95). The ion transport 
properties of this corrected channel may be augmented further by adding the potentiator, 
ivacaftor as a co-formulation with a corrector to increase function of the CFTR once it has 
reached the cell surface. 
1.5.3 Ataluren & other “skipping” modulators 
Class I variants occur due to the abnormal presence of premature termination codons. This 
class of therapy, an example of which is ataluren, aim to mask the presence of these codons 
and enable read through of the CFTR gene to create a functional ion channel protein. The 
most recent Cochrane review on ataluren for CF states that there is currently insufficient 
evidence for the use of ataluren in CF, that it is associated with potentially significant 
adverse events such as renal impairment and more research into compounds to treat this 
class of mutation would be valuable (96). 
1.5.4 Amplifiers 
Currently in development and testing are other classes of CFTR modulating drugs such as 
amplifiers, which act to increase the amount of CFTR protein synthesised by a cell. They 
could prove useful in combination with potentiators and correctors, as well as allow more 
classes of variants to be treated with CFTR modulation, such as class V and VI variants. An 
example of an amplifier is PTI-428, a drug which has been tested in monotherapy and in 
combination with a potentiator and corrector, with results looking promising (97, 98). 
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1.6 Safety, cost and the need for evidence. 
All new therapies need robust safety monitoring. This can be challenging due to the fact 
that studies are not powered to detect adverse events as in order to detect 
uncommon/rare but serious adverse events, the study may have to enrol thousands of 
participants, which is typically not feasible. There is also the possibility of ‘unknown 
unknowns’ meaning that therapies may lead to side effects we have never considered and 
therefore it is hard to know what safety measures are most appropriate or what adverse 
events may occur due to a particular therapy. A system used in the UK is the yellow card 
scheme from the MHRA, an example of which can be found in the appendix. A recent 
Cochrane review found both lumacaftor/ivacaftor and tezacaftor/ivacaftor to have modest 
improvements versus placebo in multiple outcomes including pulmonary function, quality 
of life and rates of pulmonary exacerbation. It also found tezacaftor/ivacaftor to have a 
better safety profile, as it did not show the adverse effects associated with 
lumacaftor/ivacaftor which included transient increases in shortness of breath in the short 
term, and increases in blood pressure in the longer term (99). Unlike lumacaftor, tezacaftor 
is not an inducer of CYP3A4 enzymes and does not exhibit as many drug-drug interactions 
as lumacaftor, which also affects the metabolism of its co-administered ivacaftor 
(tezacaftor does not affect ivacaftor metabolism) (100). 
These new medications are under a period of exclusivity for the pharmaceutical company 
that developed them, this accounts for their high cost. The British National Formulary 
reports a 28 day supply of ivacaftor to cost £14,000 (101). That equates to £250 per tablet 
or £500 per day. High costs have impacted the availability of these types of drugs in many 
countries, including the UK. NICE has performed a health technology assessment and 
formulate an incremental cost-effectiveness ratio (ICER) for lumacaftor/ivacaftor to assess 
if it is cost effective for the NHS to invest in this medicine. It was conducted in those aged 
over 12 years with homozygous F508del, and resulted in NICE not recommending this 
formulation (102). In those aged 12 years or under however, this medication is sometimes 
prescribed. This can lead to considering managed access schemes, where these medicines 
can be accessed on a compassionate basis. It should be noted that the issue of accessing 
high cost medications is not exclusive to CF and the ultimate decision as to whether to fund 
medicines in the UK lies with the government, taking the information provided by NICE into 
account. 
One way of collecting useful information to help make these decisions about whether such 
medicines are safe, effective and cost-effective to start or continue is by conducting a 
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systematic review. This applies for all new therapies whose efficacy and safety data should 
be collated in order to synthesise one of the highest levels of evidence to help decide 
whether interventions are safe and effective. 
2. An introduction to systematic review. 
2.1 Cochrane Collaboration 
An epidemiologist named Archibald Cochrane worked as the sole medical officer for 20,000 
German prisoners of war during the Second World War. Despite many falling ill and Dr 
Cochrane being unable to treat them all, only one of these men died due to illness. This 
made Archie consider that many illness processes are self-limiting and if the treatment he 
was giving was making any difference. He proposed the foundations of systematic review, 
and in doing so, prevented people experiencing unnecessary side effects and inefficacious 
treatments (103). 
He became an advocate of the importance of randomised controlled trials and called for a 
database to which they all should register. He also stressed the value of appraising the 
quality of research. It was only after he passed away in 1988 that the Cochrane 
Collaboration was formed (104). The collaboration brings together a network of various 
people who can play an important role in creating accessible and credible resources to 
inform health decisions (105). The register Archie Cochrane campaigned for now has over 
400,000 entries and is used to create high quality systematic reviews (103).  
The collaboration has created a process and structure to adhere to in order to create a 
systematic review of the highest standard. They produce a handbook to lay out the 
requirements and processes which must be fulfilled (106). Particular focus is made on 
assessing the credibility of the evidence, particularly the risk of bias (107). Combined with a 
rigorous and open peer review and editorial process, this means that Cochrane reviews are 
considered one of the most credible tools to aid decision making. 
2.2 What is a systematic review? 
A systematic review is a way of collecting all the available (and relevant) information to 
answer a pre-defined research question. It should follow systematic methods with the aim 
to reduce bias to draw more reliable conclusions (108, 109). 
According to the Cochrane Handbook for Systematic Reviews of Interventions (106), a 
systematic review has multiple key, defining features: a methodology which has been 
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decided ‘a priori’ and recorded in an explicit manner so that others can replicate it. This 
methodology includes clear objectives and criteria for which studies are eligible for 
inclusion in the review. The search methods ensure that all studies and sources of 
information which fulfil these criteria are identified, their quality can be assessed (typically 
using risk of bias as a measure) and their data extracted, synthesised and presented in an 
ordered fashion. 
If there is a sufficient amount of data, systematic reviews incorporate a meta-analysis into 
their data analysis. Meta-analyses employ statistical methods in order to combine results of 
trials and determine if there is an overall benefit towards the new intervention, against the 
placebo or current standard of care. It can also illustrate if any difference is significant or 
not- are the results due to chance or does the intervention make a meaningful difference?  
Meta-analyses are often represented as a forest plot. This gives us a visual representation 
of different trial outcomes and the pooled data. 
Its horizontal axis shows us the statistic which is being examined. It can show a relative 
statistic such as odds ratio or risk ratio, or it can show an absolute statistic such as absolute 
risk or standardised mean difference. The vertical axis in the middle of the plot, or the line 
of null effect intersects the horizontal axis at either 1.0 or 0 for relative and absolute values, 
respectively. This indicates the point where the exposure has no effect on the outcome, or 
there is no difference between interventions. The diamond indicates the overall result, with 
its width showing the spread of the results by showing 95% confidence intervals. Typically, 
larger sample sizes lead to narrower confidence intervals, as we are more confident about 
where the where the true result lies. 
If the outcome which your statistical figure measures is desirable e.g. remission, then 
results on the right of the plot show that the intervention has had a positive effect 
compared to the control group- the intervention is more likely to lead to the positive effect 
than your control group. 
If the outcome you are examining is undesirable, e.g. death, then it is the results on the left 
of the plot which favours your intervention- the intervention decreases the probability of 
the negative event occurring compared to control. 
Each study is represented by a square. The study’s confidence intervals are shown by a line 
spanning through the square. The wider the line, the bigger the confidence intervals and 
the less reliable are the study’s findings.  
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There is a diamond on the forest plot which represents the overall treatment effect of our 
intervention- whether the total finding of the meta-analysis favours the intervention, 
following the same logic as above. If the diamond crosses over the line of null effect 
however, this indicates the result is not statistically significant and that there is no real 
difference between intervention and control. 
Forest plots can also give a visualisation of homo/heterogeneity. If all squares/diamonds 
are favouring the same direction of effect with similar magnitudes, the results are 
homogeneous: there is less variation between the results, and they are more likely to be 
indicating a true effect. 
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Figure 4: Example of a forest plot for Cochrane systematic review of azithromycin in CF. From Southern KW et al. 
Jan 2012 (110) 
The above forest plot shows a meta-analysis for the effect of azithromycin on relative 
change of percent predicted FEV1. This shows grouped data at different time points 
showing consistency until later time points, where development of heterogeneity should be 
noted. Individual trials are each represented by a square. The size of the square represents 
its weight, which is influenced significantly by the number of participants in the study. The 
line going through each square is the 95% confidence intervals for that study’s result. The 
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diamond represents the meta-analysis at each time point. The smaller the diamond, the 
greater the confidence around the result. 
2.3 Why do a systematic review? 
The quantity of evidence, and its likely range of quality, creates a challenge for stakeholders 
to find the best source of valid information to answer their questions. The sourcing of such 
information is time consuming. 
A systematic review can form part of the solution to this, where a smaller number of people 
with the means to synthesise such evidence, find all the applicable information and can 
evaluate the quality of this information in order to provide a (relatively) accessible and 
succinct summary for decision makers to access. 
Systematic reviews are considered one of the highest levels of evidence based 
methodology (111). With rigorous standards, they combine the highest quality of primary 
research (Randomised controlled trials (RCTs)) to ascertain a more reliable answer to a 
research question. They employ statistical techniques such as weighting to further increase 
the reliability of their meta-analysis and comment on the quality of evidence which they 
synthesise. Should the authors choose (and therefore state in their protocol), systematic 
reviews can also incorporate data from sources and trials other than RCTs. This can have 
varying effects on the quality of included data (as can variation in quality of RCTs). 
2.4 The challenge of systematic reviews 
The rigid nature of systematic reviews rules out many of the “what ifs” you may see in 
clinical practice. Moreover, different decision-making groups may have different questions. 
A GP in London named Trisha Greenhalgh wrote a piece titled ‘Why are Cochrane reviews 
so boring?’ (112). Within this she comments that by the process of extracting the raw data 
to answer a “tightly focused question”, we may lose the ability to use the review for the 
actual questions we ask, or will be asked in practice. In addition, she suggests another 
“Cochrane Database of Editorials, Ideas and Opinion Pieces”, perhaps with the idea of 
complementing the facts & figures of a Cochrane review with real world experience. 
However, this may also run the risk of conflating facts and opinions at the stage of 
providing evidence, before discussions are held at local, regional, national etc. level to 
decide guidelines or commission services. 
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2.5 Heterogeneity 
Systematic reviews can include many studies. Though these studies should examine the 
same or as similar as possible interventions, populations, etc. there may be some 
differences between the results and conclusions which they report. If these differences are 
down to chance, that can be assessed but can still have an effect on the strength of 
recommendations. There may be some differences, or heterogeneity between their 
methodologies (methodological heterogeneity), the characteristics of the studied 
participants (clinical heterogeneity) or the way in which results are measured or reported 
(statistical heterogeneity) (113, 114). It is possible to identify and measure the amount of 
heterogeneity using a funnel plot and the I2 statistic (115). This allows us to quantify 
heterogeneity, acknowledge it and consider the effect on conclusions. This is a strength of 
systematic review in that it identifies such limitations in an evidence base and the need for 
a greater amount of high-quality research in a given field. 
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3. Core outcome sets for cystic fibrosis 
As I undertook the systematic review of correctors for CF, I started appreciating the 
importance of valid clinical outcome measures and the lack of a core outcome set for 
people with CF. This problem was particularly apparent in pscwCF, for whom little work on 
core outcomes has been performed. In this section I describe the importance of core 
outcome sets and later I report a study of outcomes reported in trials of pscwCF. 
3.1 What is a core outcome set? 
A core outcome set (COS) is an agreed & standardised set of outcomes which lays out the 
minimum requirements on which outcomes should be measured for trials looking at a 
similar combination of condition, intervention and patient group or in a specific field of 
interest (116-118). Formed by consensus and input of multiple stakeholder groups, the aim 
is that all trials examining similar conditions, participants and interventions will adhere to 
these standards (118). This will lead to an improvement in the consistency of results 
between trials, leading to a decrease in the use of subgroup analyses which can produce 
lower quality results. This ensures the data produced from research has a higher level of 
validity. In order to encourage uptake of the core outcome sets, it is important that the sets 
are created with a rigorous methodology. The core outcome set- standards for reporting 
(COS-STAR) framework highlights the value of this as well as the importance that the 
processes of creating a core outcome set are recorded and accessible for researchers in 
order to ensure transparency throughout the research process (118). 
3.2 The importance & value of core outcomes 
A possible limitation that can be identified by a systematic review is that trials can test the 
same/similar interventions in the same/similar population but measure different outcomes. 
This variability can make the process of collating evidence for systematic reviews more 
difficult. In 2010, the most frequently accessed and cited Cochrane systematic reviews 
described difficulties created by variations in outcome reporting (119).  By creating a COS, 
more data can be directly used in a systematic review and therefore conclusions can be 
drawn with greater confidence that the evidence will translate to practice, with outcomes 
that are more meaningful to stakeholders. This reasoning can be applied to all populations, 
interventions and specialities where research trials are conducted. 
Trials concerning variant specific therapies have largely been tested in adults, adolescents 
and older children. Though some trials have now began including 0-5 year olds, for 
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example, the KIWI trial, which examined Ivacaftor in 2-5 year olds with at least one class 3 
(gating) variant (120), less is still known if these drugs are safe and effective (or not) in pre-
school children. Trials in pscwCF have tended to be open label, with the assumption that 
efficacy data are translatable from trials on older patients.  This is understandable and part 
of most paediatric investigation plans, but there should be an effort to determine 
effectiveness in this age group, despite the challenges.  
Efficacy outcomes can be measured well in RCTs, as changes are often detected within the 
trial period. However, they are not always translatable to patients outside of the clinical 
trial. Outcomes may indicate efficacy within the trial but not indicate how this efficacy will 
impact the everyday wellbeing of patients. 
Core outcome sets can also help overcome selective outcome reporting by stating the 
expectations of what should be reported and raising awareness among authors and readers 
of the problems associated with selective outcome reporting. Work published in 2010 
surveyed 283 randomly selected Cochrane reviews and their 2486 included trials. It found 
that 157/283 (55%) Cochrane reviews did not include complete data for their primary 
outcomes. 155/2486 (6%) of included trials had measured the primary outcome of the 
Cochrane review which they had been included in, but then neglected to report it (121). 
This highlights the significant prevalence of this problem and the effect it has on systematic 
review and meta-analysis. 
3.3 The COMET Initiative 
The COMET initiative (Core Outcome Measures in Effectiveness Trials) provides a 
framework for those developing core outcome sets for all trials examining a specific 
condition (116). In addition to providing consistent design, trials will include outcomes that 
reflect real-life of patients, this also makes it easier to include data into meta-analyses. This 
will mean that results from more trials can be included and a more accurate consensus may 
be reached. 
When the search term ‘cystic fibrosis’ is used to search the COMET database, two papers 
are identified that report discussions regarding core outcome measures for cystic fibrosis at 
previous workshops/conferences (122, 123). There is a paucity of guidance for those 
conducting trials in CF and these discussions make little specific referral to pre-school 
children aged 0-5. There are relatively few trials in pscwCF, and it is especially important to 
make sure that those trials provide optimal information using outcome measures that 
equate to long term wellbeing.  
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For the second part of my MPhil project, I will review outcomes which are reported in trials 
in this age group with the aim of informing the process of determining the most useful 
outcomes for these trials.  
A brief review regarding outcomes in multiple respiratory diseases, including CF was 
performed in 2010 (124). It describes several points for 0-6 year olds but requires more 
detail and an update is necessary due to new trials being performed since 2010. This review 
makes the important point that surrogate outcomes do not equal a direct clinical benefit to 
patients and may not equal a change in a pragmatic outcome. It found that in general, trials 
in CF included quality of life, pulmonary function, rates of pulmonary exacerbation, growth, 
microbiology, inflammatory markers, nasal potential difference and radiological imaging, 
with the target age group influencing which outcomes are selected. This review also points 
out that in pscwCF, outcomes are particularly limited due to difficulty with spirometry, 
imaging resolution not being able to pick up the usually very small changes to airways at 
this age, difficulty collecting sputum samples and the fact that the typically used CFQ-R 
quality of life questionnaire is not applicable to pscwCF. It finishes by saying that during the 
next 10 years from when it was written, trials of interventions which use improved 
outcome measures will lead to greater benefits for these children thanks to earlier 
identification and treatment of disease (124). 
OMERACT (Outcome Measures in Rheumatology), has promoted the use of core outcome 
sets for rheumatology trials for twenty years (125). Earlier still, in 1979, the WHO produced 
a handbook for how cancer trials should report results (126). COMET was launched in 
Liverpool in 2010 (125). Although numerous specialities acknowledge the value that core 
outcome sets can provide, there is a lack at any age group in the field of cystic fibrosis. A 
core outcome set taskforce for CF (COST-CF) headed by Professor Alan Smyth in 
Nottingham have registered with COMET (127), but efforts to fund this project are yet to be 
successful. 
3.4 The utility of core outcome sets 
Asthma is an example of where considerable work has been done to determine the most 
important outcomes, both for children, young people and adults (128, 129). Challenges 
were identified during the development process for this COS included encouraging people 
to consider the idea that although you can measure a particular endpoint, it doesn’t always 
mean that it is useful to do so; as numerous stakeholders considered the idea that if there 
was a means to measure an endpoint, it may as well be measured. Another challenge in 
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this work which aims to provide as much value to as many stakeholders as possible was the 
different approaches and reasons that stakeholders had for being involved in research trials 
and the difficulty in ensuring a COS satisfies them all: patients may want to be involved to 
see if the next new therapy makes a difference to their wellbeing, pharmaceutical 
companies want to ensure their drug is safe and effective to take to market, commissioners 
want to learn if an intervention is cost effective and so on. These challenges are important 
to consider for the creation of a future COS in CF. Further work is also currently being 
undertaken to further refine core outcomes for asthma, accounting for factors such as 
severity of asthma. Examples of such include the coreASTHMA project and the PERN 
asthma working group (130, 131). 
Another good example of work to develop core outcome sets is for rheumatoid arthritis, 
with work first going back as far the 1980s and still ongoing today to update and improve 
core outcomes to keep pace with the standards of research (132-134). Work in this field has 
included many stakeholders, including a lot of focus on patient perspective which has been 
considered a very important component in determining core outcomes (135, 136). 
3.5 Development of a core outcome set 
There is a standard methodology agreed upon for the process of developing a core 
outcome set (116). It should involve engaging with different stakeholders, for example 
health professionals, policy makers and the people who use these interventions, as well as 
their parents or carers. The decision on which stakeholders should be involved for each COS 
set will be determined by discussion about the scope of each COS, existing knowledge on 
the topic concerned and what is feasible (117). There are examples showing that patients 
aren’t often involved in these discussions, but when they were involved, they came up with 
outcomes which the other stakeholders had not considered. Good examples again come 
from the field of rheumatology; at a patient perspective workshop as part of an OMERACT 
meeting, they found that more emphasis needed placing on subjective experience of 
people living with rheumatoid arthritis including sense of wellbeing, disrupted sleep and 
fatigue as well as using less jargon and continuing to make patients an important 
component in outcomes research (137). In another publication, interviews with 23 people 
with rheumatoid arthritis identified 60 outcomes which these people sought from their 
treatment, in addition to the outcomes already commonly considered in trials of 
treatments for this condition (138).  
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There is also mention that as well as setting out what should be measured by trials, there 
should also be a validated tool to measure these where possible. An illustrative example of 
this which has previously been used by members of the COMET team (117) is a systematic 
review regarding breast reconstruction which found that 906 different outcomes were 
measured, but only 20% of these outcomes were measured using a validated tool (139, 
140). An example of an outcome in CF that is difficult to validly quantify is pulmonary 
exacerbations, which can incorporate a degree of subjectivity as to how they affect 
individual people with CF rather than having a valid measure of severity that is reproducible 
across all people with CF. 
 The Consensus-based Standards for the selection of health Measurement Instruments 
(COSMIN) is a Dutch body with the aim to help assess the validity of measurement tools 
and also select a tool which has already been validated to measure a given outcome (141). 
There is also another initiative called PROMIS (Patient-Reported Outcomes Measurement 
Information System) which provides validated measurement tools for patient reported 
outcomes relating to physical, mental and social health in chronic diseases. They also 
include tools specific to children and parent proxy tools including measures with the 
potential to be applied to pscwCF such as life satisfaction, physical activity and peer & 
family relationships (142). 
A discussion on the value of core outcomes and their valid measurement for cystic fibrosis 
research was published in 1994. This discussion included the importance of determining a 
validated measure of outcomes for multiple parameters in young children aged 0-5. These 
parameters included pulmonary function testing, a validated disease severity score for 
young children, reliable radiological assessment, quality of life and wellbeing (122). Our 
work is different to this as it exclusively examines preschool children with CF and we 
further build upon its work by comprehensively recording the outcomes reported by the 
protocol, methods and results of Cochrane systematic reviews and their included trials in 
pre-school children. 
A starting point on the journey to develop a COS for pscwCF is a review to record what 
outcomes have currently been measured in this age group. 
 The next steps of the COMET process would involve engaging with stakeholders through 
both discussions and a Delphi survey. A list of possible outcomes is devised, and 
stakeholders are asked to select which of these is important to them and also suggest any 
which may have been missed (round 1). The responses are collated, and a summary is sent 
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back to each respondent, along with a reminder of their round 1 responses. After reviewing 
the summary, they then decide whether they want to change their responses (round 2). 
The results are collated again by the researchers, who can decide they have adequate 
information or can continue asking respondents for rounds of responses. Upon completion 
of the survey part, respondents are invited to a group discussion about the results to again 
help refine what are the best outcomes to measure. A report is then produced on what the 
experts and stakeholders consider to be the most important outcomes (143). 
3.6 Possible difficulties for core outcomes 
Some pragmatic measures in this age group may be difficult to use as a reliable measure of 
how a pre-school child is managing with their CF. A pragmatic measure is one which directly 
shows the effect of an intervention on the person and their family. Some examples of 
pragmatic outcomes that may be useful in this age group are the frequency of antibiotics, 
number of hospitalisations, and parent reported outcomes (typically based on the 
symptoms of their child, but these measures need appropriately validating). 
Surrogate measures can provide valuable information and are often used. Surrogate 
measures are an investigation or physical sign which can be used as a substitute for a more 
meaningful measure of a person’s quality of life, survival or functional status, and are 
sometimes referred to as biomarkers. They should predict the effect of the intervention 
(144). An example of a surrogate measure would be sweat chloride, infant pulmonary 
function tests or lung clearance index. 
 A secondary analysis of the ISIS study (Infant Study of Inhaled Saline) looked at the use of 
infant pulmonary function testing as endpoints in an RCT of infants with CF. It concluded 
that pulmonary function tests in infants were not appropriate primary endpoints due to the 
difficulty of obtaining acceptably useful data and the near-normal results they provided in a 
young age group where significant airway damage may not have occurred. Stated that 
more modern measures such as that of LCI may be better at giving a picture of pulmonary 
status in this group, but the fact that its results differ to those provided by infant 
pulmonary function tests, in that one tool may measure as normal whereas the other 
measures as abnormal (or vice versa) shows they may reflect different parts of 
pathophysiological processes occurring in the lungs, and are not analogous to one another 
(145). Imaging may not be sensitive enough to detect small changes which may have 
developed. It is impossible to produce a good sputum sample in most pscwCF and 
oropharyngeal swabs are a less reliable test (124).  
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A commentary from 2007 discusses the difficulties experienced when collating information 
from multiple trials for systematic reviews, such as measurement of a similar endpoint 
using different tools. It highlights a review of over 2000 trials for treatments of 
schizophrenia. They identified over 600 different interventions, but interestingly found an 
even greater number of 640 different mental health scoring tools from these trials. Having 
such a large number of different measuring tools for the same or similar outcomes makes it 
difficult to select the most valid and reliable tool. The same 2007 commentary also points 
out the importance of how a COS can help overcome selective outcome reporting (a 
sentiment also shared by COMET) (121, 146, 147). 
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4. Cochrane systematic review 
4.1 Background 
This work represents a substantial update of a previously published systematic review 
concerning correctors (99). The use of these medicines was examined in people with CF 
with at least one class II variant and they were also tested as single agents (monotherapy) 
and some as part of a combination of a corrector and a potentiator (discussed above), this 
was known as dual combination therapy. 
The previous version found that correctors, when used in monotherapy for class II variants 
showed no or little benefit versus placebo in the outcomes measured in the review. Dual 
combination showed modest improvement in some measures significant adverse events 
were reported for lumacaftor/ivacaftor (99).  
The area of novel CFTR modulating therapies is changing rapidly, and it is important to 
incorporate new data when available to inform up to date decision making such as health 
technology assessments. New trial data had been released since the latest version and 
therefore an update is valuable. As this is an update, the rationale for the systematic review 
and eligibility criteria were unchanged. 
 4.1.1 Description of the intervention 
We have learnt more over recent years as to how the different CFTR variant classes affect 
the synthesis, processing and trafficking pathway of the CFTR protein, and therefore where 
we can intervene to aid the presence of a functional protein at the cell surface. As class II 
variants lead to defects in folding and intracellular trafficking. The intervention to target 
this problem must therefore correct or mask the folding of the protein and are hence 
known as ‘correctors’. Correctors are small molecule drugs which were discovered by either 
the testing of compounds in known medications, plants, foodstuffs etc. already known to 
have an effect on CFTR or other ion channels; or by high throughput screening which 
involves testing many small molecule compounds to see if they have an effect on CFTR 
function (148). 
4.1.2 How the intervention might work 
The aim of correctors is to facilitate the CFTR protein to overcome its class II trafficking 
defect. We do not know for certain their mechanisms of action, but it is thought correctors 
help to mask the folding defect so that the ion channel represents a CFTR not affected by a 
CF causing variant (a ‘normal’ or wild type CFTR), allowing it to reach the cell surface 
37 
 
without being broken down. Once at the cell surface this class II CFTR may still have 
reduced function and so a potentiator medication may also be required to increase the 
probability that the chloride channels will be open (149). 
4.1.3 Why it is important to do this review 
Correctors have only been in widespread use for a short number of years and new 
correctors are being synthesised and tested all the time, with results of new trials being 
published frequently. It is therefore important that this systematic review keeps pace with 
the evidence to have an up to date assessment of the benefits and harms of these drugs 
over a longer time period. As there is often a significant cost associated with these 
medicines it is important for such information to be available to stakeholders and funding 
bodies (99). 
4.1.4 Objectives 
To assess the efficacy of CFTR corrector medications on outcomes considered as clinically 
important, as well as their potential harms and adverse effects in children and adults with 
CF and at least one copy of a class II CFTR variant. 
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4.2 Methods for Cochrane systematic review 
 
4.2.1 Identifying potentially eligible studies 
The data search was carried out by an information specialist in the Cochrane Cystic Fibrosis 
& Genetic Disorders (CFGD) group. The information specialist searched the Cystic Fibrosis 
Trials Register, maintained by the Cochrane CFGD group to keep a record of all clinical trials 
conducted in the field of CF. This is compiled with results from CENTRAL, the Cochrane 
Central Register of Controlled Trials. The register also compiles search results of MEDLINE 
(conducted every quarter) and search results of Embase to 1995. The terms used to search 
this register was ‘drugs that correct defects in CFTR transcription, translation or processing’, 
with which applicable studies have been tagged in the register. 
Additionally, hand searching of the journals Pediatric Pulmonology and the Journal of Cystic 
Fibrosis is performed. Clinical trials registers were also searched as another means of 
ensuring no eligible trials were missed. This was also performed by the information 
specialist, according to the previously determined protocol. The clinical trial registers which 
were searched were: 
• The European Medicines agency; clinicaltrialsregister.eu 
• The US National Institute of health; clinicaltrials.gov 
• The World Health Organisation; who.int/ctrp/en 
All of these trial registers were searched with the terms: Cystic fibrosis AND (VX OR 
corrector). VX refers to the abbreviation used by the pharmaceutical company Vertex to 
test their new experimental drugs e.g. VX-445. 
Also, to identify further studies which may be eligible, bibliographies of already included 
studies were checked, as well as contacting their authors and known leaders in CF research 
and pharmaceutical companies who are known to be working on the development of CFTR 
correctors. This was performed by both the information specialist and myself (JM), 
according to the already determined protocol. 
Finally, in order to identify as yet unpublished work, the abstract books of three large CF 
conferences were searched by the information specialist, according to the protocol. These 
conferences are: The International Cystic Fibrosis Conference, The European Cystic Fibrosis 
Conference and the North American Cystic Fibrosis Conference. Once the search identified 
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potentially eligible papers, we sought the abstracts and full versions of the citations, where 
available.  
 
4.2.2 Assessing eligibility 
Cochrane requires eligibility assessments and data extraction for trials to be performed 
independently by at least two people. Therefore, two of the team (JM & IS) used the 
criteria provided in the Cochrane study selection, quality assessment and data extraction 
form to identify those studies which were eligible. Those criteria were: 
• Appropriate study design- We included parallel design RCTs. We did not include 
cross-over studies as correctors address the underlying defect and would alter the 
course of disease if effective, having an impact on results. 
• Relevant participants- does the included study population fit with your criteria? We 
included participants of any age and any level of disease severity. They should have 
one or two class II CFTR variants. 
• Relevant interventions- is the study looking at an appropriate intervention? We 
were looking specifically for corrector medications to overcome F508del variants 
affecting CFTR. 
• Relevant outcomes- does the study measure/report on outcomes which your 
review is including? Our outcomes of interest are listed below. However, if trials of 
a drug considered to be a corrector did not report outcomes stated in the review, 
we still considered whether it had any valuable information. 
If the answer was yes to all of the above criteria, the study was eligible for inclusion in 
the Cochrane review. If the two people assessing eligibility found they had 
disagreements over eligibility, they discussed them to try and reach a consensus. If 
necessary, a third team member would arbitrate. 
In the case of only abstracts being identified for eligible studies, which stated further data 
would be available soon, or not all data was thoroughly included, we contacted authors for 
further information regarding the design, methodology and results of the survey. This was 
performed according to standard Cochrane methodology, which is adhered to in the 
previously determined protocol, but is performed on newly identified citations from a new 
data search for this update. 
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4.2.3 Outcomes recorded 
These outcomes were determined by reviewing similar interventions in cystic fibrosis. 
There was also discussion between multiple stakeholders, including experts in the field, trial 
investigators, other clinicians and patients/families. These processes then led to eliciting 
what outcomes are most often of interest and value to multiple stakeholders. The 
outcomes were not changed in this latest update of the review and therefore I (JM) was not 
involved in determining the outcomes to be examined. 
4.2.3.1 Primary outcomes: 
1. Survival 
2. Quality of life (which used a validated quantitative measure, for example the Cystic 
Fibrosis Questionnaire- Revised (CFQ-R) (150)) 
a. Total quality of life score 
b. Any sub-domains which may have been reported 
3. Physiological measures of lung function- litres or percent predicted according to 
demographics of the patient. 
a. Relative change from baseline of FEV1 (Forced expiratory volume after one 
second) 
b. Absolute change from baseline in FEV1 values 
c. Absolute values and change from baseline for FVC (Forced vital capacity) 
d. Lung clearance index 
e. Other relevant measures of lung function 
4.2.3.2 Secondary outcomes: 
1. Adverse effects- We classified adverse events according to: 
a. Mild- therapy did not need to be stopped. 
b. Moderate- therapy stops, then adverse effect stops 
c. Severe- adverse effect still persists after stopping therapy, or an effect which is 
life threatening or debilitating. 
d. Other adverse event due to the experimental therapy which cannot be 
classified by the above categories. 
2. Hospitalisation 
a. Number of days spent in hospital 
b. Number of admissions to hospital 
c. Time to next hospital admission 
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3. Measures of attendance for work or school (for example, number of days missed 
due to illness) 
4. Use of extra antibiotics (total number of antibiotic courses, or time to next 
antibiotic course)- incorporating the occurrence of pulmonary exacerbations. 
a. Oral antibiotics 
b. Intravenous antibiotics 
c. Inhaled antibiotics 
5. CFTR function- Change from baseline of sweat chloride level 
6. Radiological scoring system for measuring lung disease (any score) 
a. Chest X-ray scores 
b. Computerised tomography scores 
7. Respiratory pathogen acquisition 
a. Pseudomonas (P.) aeruginosa 
b. Staphylococcus (S.) aureus 
c. Haemophilus (H.) influenzae 
d. Other respiratory pathogens clinically relevant to cystic fibrosis patients 
8. Eradication of respiratory pathogens 
a. P. aeruginosa 
b. S. aureus 
c. H. Influenzae 
d. Other respiratory pathogens clinically relevant to cystic fibrosis patients 
9. Measures of nutrition & growth- relative change from baseline, including z scores 
or centiles 
a. Weight 
b. Body Mass Index (BMI) 
c. Height 
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4.2.4 Data extraction 
Two authors (JM & IS) performed data extraction for the newly eligible studies, if there was 
disagreement a third author arbitrated where necessary (KWS).  
For this update, a new data extraction spreadsheet was created by JM, based on that 
provided by the Cochrane Collaboration. Due to the complex design of some of the trials 
however, adaptations were required to incorporate the multiple measures taken at 
different time points, for a range of doses and different combinations of CFTR mutations. 
Some trials even included different versions of the same molecule, for example Ivacaftor 
and VX-561, a deuterated form of Ivacaftor which is considered more stable and therefore 
taken once per day as opposed to the usual twice per day (151, 152). An example of this 
new data extraction sheet can be found in the appendix. 
Eligible papers were read and outcomes from the list above extracted and input to the data 
extraction form. Data was classified according to timeframe: immediate (up to and 
including one month), short term (over one month to six months) or long term (over six 
months). 
4.2.5 Risk of bias 
Two authors (JM & IS) were required to assess the risk of bias in included trials. Cochrane 
provide a risk of bias tool and a chapter in their handbook to provide guidance on the 
domains to consider when assessing a study’s risk of bias (107, 153). These domains are:  
• Procedure for randomisation- what method was used in order to create the process 
of randomising patients? Was it done by someone independent of the study itself? 
And will it produce sufficiently comparable groups? This is examining selection bias. 
• Allocation concealment- Was it possible for study personnel or patients to 
determine the allocation sequence before or during enrolment? This is also looking 
into selection bias. The author should find out the method used to conceal 
allocation. 
• Blinding of the intervention from participants, clinicians and other study personnel- 
What methods were used to mask which intervention a participant was given? 
Were these efforts effective? This examines performance bias. 
• Blinding of outcome assessment- What steps were taken to prevent those people 
who are measuring and analysing the outcomes of interest in the study, from 
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learning which intervention a patient received? Was this blinding effective? This is 
an example of detection bias. 
• Incomplete outcome data- Was every patient who was originally enrolled and 
randomised then accounted for as part of the results for each outcome? Are any 
patients who were excluded or dropped out accounted for, along with reasons 
explaining their attrition? This is examining attrition bias. 
• Selective reporting- were all outcomes that were stated in the protocol/methods 
then reported in the results? If there were any outcomes which were not measure, 
were there any reasons why? If yes, they should be stated transparently. This is 
looking at reporting bias. 
• Other bias- an opportunity for review authors to identify any other concerns 
regarding bias which the above criteria don’t cover. 
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4.2.5.1 The different domains of bias 
The Cochrane risk of bias assessment tool looks for the risk of multiple domains of 
bias. These domains are: 
• Selection bias- when a cohort in a study has a systematic difference (other 
than the intervention or exposure) from the population of interest. This can 
lead to a systematic difference in measured results. An example could be 
an intervention intended to be used mainly for elderly people being tested 
in a cohort of young adults. 
• Reporting bias- this can occur when the reporting of results is influenced by 
other factors. It comprises several sub-categories (154): 
o Publication bias- work is more or less likely to be published 
depending on the findings e.g. very positive or highly significant. 
This can also lead to: 
o Time lag bias- if work is high profile or produces very positive or 
significant results, it is more likely to be published quicker. 
o Multiple/duplicate publication bias- depending on results, work 
may be submitted/published multiple times to different 
journals/conferences etc. 
o Location bias- depending on results, work may be published in 
journals which are easier/more difficult to find or access, or with 
different impact factors. 
o Citation bias- despite being relevant, work may not be cited if its 
results don’t fit with a point that is being made. 
o Language- work is more likely to be published in English if it shows 
favourable results. 
o Outcome reporting bias- some studies may not fully report the 
results of all the outcomes which they stated in protocol or 
methodology. 
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• Performance bias- can occur when the researcher or the participant is 
aware of if they have been allocated to intervention or control. It can lead 
to differences between care given to participants and can lead to the true 
treatment effect of the intervention being disrupted or masked. 
• Detection bias- this occurs due to differences in how the outcome of 
interest differs e.g. different people or using a different piece of equipment 
to measure an outcome. 
• Attrition bias- this can happen when there is incomplete outcome data for 
all participants due to participants pulling out of trials or being lost to 
follow up. This attrition of patients may occur unequally between the 
intervention and control groups and there may be systematic differences 
between those who are more likely to drop out and those more likely to 
remain in the trial, for example participants who are more severely ill may 
be more likely to drop out, leaving the more well participants to continue in 
a cohort which is now not fully representative.  
Publication bias can occur if a trial finds negative results and therefore decides to withhold 
from publishing them (155). This can have the consequence of making the consensus of 
literature inaccurate from the true answers it should hopefully be able to give us and may 
shape the direction of future work on a sub-optimal course. 
To check for the possibility of publication bias, one of the team members (a statistician, 
SJN) would have aided in the construction of a funnel plot, which plots the number of 
patients in a given study, against a measure of treatment effect.  Once this was plotted for 
every included study, we would have checked if the funnel plot is symmetrical or not. If it 
was asymmetrical, this may be due to publication bias. However, it should be noted that 
there are other causes of asymmetrical plots: methodology of the studies, small sample 
sizes and chance can all have an effect. In order to create a meaningful funnel plot, you 
require at least 10 trials to be included in your review. 
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Funnel plots often show standard error (y axis) as a measure of study power, the scale of 
which is inverted. This means the more powerful studies with smaller standard error are at 
the top of the scale. This is plotted against a measure such as mean difference or odds ratio 
(x axis). The included studies are plotted on this graph and should spread out and, assuming 
no bias is present, 95% of studies should be included within a funnel extending from zero at 
the top of the inverted y axis scale, to 1.96 standard errors either side of the scale on the x 
axis (156). 
 
Figure 5: An example of a funnel plot comparing relative change in % predicted FEV1 for azithromycin versus 
placebo. From Macrolide antibiotics for cystic fibrosis. From Southern KW et al. 2012 (110) 
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4.2.6 Measures of treatment effect 
Continuous outcomes were measured by first finding their mean change from baseline and 
their standard deviations. Where necessary we calculated mean change ourselves, 
providing that we had measures for the same value at baseline and the end for the studies. 
These values can then be used to find a mean difference with 95% confidence intervals. 
For binary outcomes, overall treatment effect was calculated using a pooled odds ratio with 
95% confidence intervals.  
For time to event outcomes, we used hazard ratios and their 95% confidence intervals. 
Outcomes that were reported by multiple studies were put into meta-analyses to find an 
overall representation of treatment effect. Forest plots were drawn to illustrate magnitude 
of effect and examine for consistency (homogeneity) of results. 
4.2.7 Heterogeneity 
No two studies are the same. The differences between them are collectively termed 
heterogeneity, of which there are several types (157). 
Clinical heterogeneity is the differences that exist between the participants of the study; 
their age, their sex or medical history are possible examples. 
Methodological heterogeneity is where there are variations in the design of the study e.g. 
length of test period, parallel vs. crossover. It can also relate to differences between risks of 
bias, including the different sub-domains (mentioned above).  
Statistical heterogeneity is any differences between the effects that different trials are 
trying to measure. This is particularly notable during meta-analysis, where we must ask- 
“Are these effects similar enough for us to combine as part of the same analysis? Are they 
measuring the same thing?” Both clinical and methodological heterogeneity can lead to 
statistical heterogeneity. These reasons are why when work such as systematic reviews & 
meta-analyses mention heterogeneity, they are most often mainly referring to statistical 
heterogeneity (157). 
There are several ways to look for possible heterogeneity. One way to is to examine 
confidence intervals for values of the same effect between different studies; if there is little 
overlap, this may raise suspicion of heterogeneity. You can also use the Chi2  test which can 
give information about whether differences between results are due to chance or not. A 
Chi2 statistic that is large compared to its degree of freedom can suggest the variation in 
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effect measures is not just due to chance. The method that is commonly used in Cochrane 
reviews is the I2 statistic, which builds upon the Chi2 statistic using the following equation 
(158, 159):  
𝐼2 = (
𝑄 − 𝑑𝑓
𝑄
) × 100% 
In this equation, Q is the Chi2 statistic and df is its degrees of freedom. 
The output is a percentage value, which can be interpreted as such (157): 
0-40%: less likely to be important heterogeneity. 
30-60%: may be some moderate heterogeneity. 
50-90%: may substantial heterogeneity. 
75-100%: heterogeneity is considerable. 
The value of the I2 statistic is limited to the strength of the evidence for heterogeneity such 
as the confidence interval for I2 or the P value of its respective Chi2 test (157).  
We planned that in the eventuality that heterogeneity between studies was found, we 
would perform subgroup analyses to account for potential confounders. The confounders 
that would be accounted for are: age (children under 18 vs. adults age 18 or over), gender 
and class of mutation. Subgroup analyses could only be performed if there were at least 10 
studies. 
4.2.8 Sensitivity analysis 
Sensitivity analysis is a method of attempting to find how uncertainty in a given information 
source affects the overall (un)certainty of your meta-analysis. It is done by performing the 
same meta-analysis; once where you include all applicable studies, and a second time when 
you’ve excluded those studies with a high risk of bias. The two meta-analyses are then 
compared to see if there is any impact on results from the potential biases. 
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4.3 Results of Cochrane systematic review 
4.3.1 Context of this result section 
This work represents a substantial update of the first review published in 2018. For this 
review I have re-assessed outcome data from the first review and have included new data 
from four studies that are newly available since the first review. These studies examined a 
monotherapy (Horsley (160)) and various triple combination therapies (Davies a, Davies b 
(152) and Keating (151)). 
This work will critically appraise the new studies and present outcomes in the context of 
the first review. 
4.3.2 Study selection 
4.3.2.1 Included studies 
Monotherapy 
Eight studies were included, with a total of 344 participants (160-167). The drugs which 
were examined in monotherapy were sodium phenylbutyrate (4BPA), N6022, 8-
cyclopentyl-1, 3-dipropylxanthine (CPX), cavosonstat and lumacaftor. There was one newly 
added study (Horsley (160)) which compared FDL169 at doses of 400 mg (n = 6), 600 mg (n 
= 6) and 800 mg (n = 8), each taken three times daily, versus placebo (n = 7) for 28 days. 
Dual combination therapy 
Six studies were included in the previous edition of this systematic review, they included a 
total of 1898 participants (100, 161, 168-170) (the TRAFFIC and TRANSPORT studies are 
included as part of a single reference ). An additional study (PROGRESS) provided safety 
data for the analysis (171); despite progress being open label continuation of TRAFFIC and 
TRANSPORT, it was felt that the safety data it provided was important to be included and so 
an exception was made to include it. Its efficacy data was not included. 
Four studies compared lumacaftor-ivacaftor versus placebo in 1376 participants (161, 168, 
170). Two studies compared tezacaftor-ivacaftor versus placebo in 522 patients (100, 169). 
No new studies of dual combination therapies were identified by this update. 
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Triple combination therapy 
Three newly identified triple combination studies consisted of one phase 1 study and two 
phase 2 studies. All were of parallel design. The studies included a total of 255 participants.  
Their sample sizes consisted of 12 for Davies 2018 (a) (152), 121 for Davies 2018 (b) (152)  
and 123 for Keating 2018 (151). The Davies 2018 phase 1 and 2 studies- ‘a and b’, are 
published as part of the same paper (152).  
Duration of these studies ranged from 14 days (Davies 2018 (a) ) to 4 weeks (Davies 2018 
(b) & Keating 2018 (151)). 
All studies were multi-centre. Full texts were available for all 3 of the new triple 
combination studies. 
The two Davies studies tested VX-659-tezacaftor-ivacaftor combination therapy. The phase 
1 study (a) compared a single dose level of 120 mg VX-659 taken twice daily in combination 
with tezacaftor 100 mg once daily plus ivacaftor 150 mg twice daily for 14 days in 
participants with a compound heterozygous F508del/MF genotype (152). The following 
phase 2 study, Davies (b), tested VX-659 in ascending once daily doses of 80 mg, 240 mg & 
400 mg in participants with an F508del/MF genotype for 4 weeks. In a separate group of 
people with this same genotype, investigators studied the regimen of VX-659 400 mg once 
daily plus tezacaftor 100 mg once daily plus VX-561 (deuterated ivacaftor) 150 mg once 
daily versus placebo for 4 weeks. Davies (b) also included a group of patients with 
F508del/F508del genotypes who took VX-659 400 mg plus tezacaftor 100 mg once daily 
plus ivacaftor 150 mg twice daily versus the control of tezacaftor 100 mg once daily plus 
ivacaftor 150 mg twice daily, which the study considered as the standard of care for people 
with CF who have this genotype (152). 
Keating, a phase 2 study tested VX-445-tezacaftor-ivacaftor combination therapy in 
ascending doses of 50 mg, 100 mg and 200 mg once daily of VX-445 in triple combination 
with tezacaftor 100 mg once daily plus ivacaftor 150 mg twice daily in participants with an 
F508del/MF genotype. In another group of participants with the F508del/MF genotype, the 
study tested VX-445 200 mg once daily plus tezacaftor 100 mg once daily and VX-561 
(deuterated ivacaftor) 150 mg once daily. Additionally, in a group of patients homozygous 
for F508del, they also tested VX-445 200 mg once daily plus tezacaftor 100 mg once daily 
and ivacaftor 150 mg twice daily (151). 
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4.3.2.2 Excluded studies 
From this latest search, 5 references relating to 3 studies were excluded. 1 reference 
related to EXTEND , an open label extension of the already included EVOLVE tezacaftor-
ivacaftor dual combination trial (172). 2 references (173, 174)  related to a crossover study 
of tezacaftor-ivacaftor in people with CF who have an F508del/residual function genotype 
(175). 2 references related to a study of a drug called QR-010, an antisense-oligonucleotide 
which we did not consider to be a corrector for F508del CFTR variants (176, 177).  
The first version of this review had excluded 11 studies from its literature search. Six were 
excluded for being a crossover design (175, 178-182), two were single assignment studies 
(183, 184), one was not randomised (185), one was a pre-clinical lab based study (186) and 
one studied general gene therapy and not variant specific therapies (187). 
4.3.2.3 Ongoing studies 
Following results from this latest data search, 17 studies are listed as ongoing.  
7 studies are examining monotherapy. 2 of which are studying GLPG2222 (188-191). 2 are 
studying PTI-428 (NCT02718495, NCT03258424). One study is examining roscovitine (192). 
Another study is looking at GPBA (NCT02323100) and one study is examining PTI-801 alone 
and in combination with PTI-428 (193). 
4 ongoing studies are looking at dual combination therapy. 4 are comparing tezacaftor-
ivacaftor, 3 in participants with F508del/F508del genotypes and 1 in participants with a 
genotype of F508del/variant responsive to ivacaftor.  
3 ongoing trials are studying triple therapy combination. One is examining VX-152-
tezacaftor-ivacaftor (NCT02951195). One is studying VX-445-tezacaftor-ivacaftor in people 
with CF with either F508del/F508del or F508del/MF genotypes as well as people without CF 
(NCT03227471). A third study is evaluating the addition of cavosonstat to people with CF 
with the F508del/F508del genotype who are already taking lumacaftor-ivacaftor 
(NCT02589236).  
A more detailed summary of ongoing studies is available in the appendix. 
 
52 
 
4.3.3 Study quality 
Below is a table summarising the results of risk of bias assessments for the newly added 
studies from this update. Risk of bias assessments of all remaining included studies can be 
found in the appendix. 
For table 1, green indicates a low risk of bias, yellow an uncertain risk of bias and red a high 
risk of bias (none shown). Please see tables 2-5 below for a breakdown and reasoning on 
why each domain has been judged to have its respective risk of bias. 
 
 Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Blinding of 
participants 
and 
personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment 
(detection 
bias) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) 
Other bias 
Davies 
2018 (a) 
       
Davies 
2018 (b) 
       
Horsley 
2017 
       
Keating 
2018 
       
Table 1: Risk of bias summary of newly included studies from latest update of Cochrane systematic review. 
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Bias domain Authors 
judgement 
Support for judgement 
Random 
sequence 
generation 
(selection bias) 
Unclear 
risk 
States that participants are randomised but does not 
state the method by which they are randomised. 
Allocation 
concealment 
(selection bias) 
Unclear 
risk 
Does not state methods of allocation concealment. 
Blinding of 
participants and 
personnel 
(performance 
bias) 
Unclear 
risk 
Does not state who was and was not blinded during the 
study. 
Blinding of 
outcome 
assessment 
(detection bias) 
Unclear 
risk 
Does not state how outcome assessors were blinded 
during study. 
Incomplete 
outcome data 
(attrition bias) 
Low risk All participants who were randomised are accounted for. 
Selective 
reporting 
(reporting bias) 
Low risk All outcomes stated in the methods are reported in the 
results. 
Other bias Unclear 
risk 
As the only information available was as part of a poster 
and a full detailed publication has not been published, it 
is difficult to say with any certainty whether there are 
other sources of bias in the process of this study. 
Table 2: Risk of bias table for Horsley 2017. 
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Bias domain Authors 
judgement 
Support for judgement 
Random 
sequence 
generation 
(selection 
bias) 
Low risk Randomisation list made by Vertex Biostatistics or a 
randomisation vendor. Final list reviewed and approved by a 
designated unblinded statistician who is independent of the 
study team. Interactive web response system used to assign 
participants to treatment. 
Allocation 
concealment 
(selection 
bias) 
Low risk Random allocation independent of study team. Use of 
interactive web response system. 
Blinding of 
participants 
and personnel 
(performance 
bias) 
Low risk All participants, site personnel and Vertex study team were 
blinded to allocation. Protocol sets out conditions when blinding 
could/should be broken. 
Blinding of 
outcome 
assessment 
(detection 
bias) 
Unclear 
risk 
All authors were only allowed access to study data after they 
were unblinded. No mention is made of other outcome 
assessors (e.g. clinicians who were not authors but were 
involved in seeing participants and measuring outcomes of 
interest) and whether there was a possibility of them knowing 
allocated intervention. 
Incomplete 
outcome data 
(attrition bias) 
Low risk All participants who were randomised are accounted for. 
Selective 
reporting 
(reporting 
bias) 
Unclear 
risk 
States in methods that it would measure 12-lead ECG and vital 
signs, though these may have been measured, they are not 
stated in results or supplement regardless of if they were 
unremarkable or not. 
Other bias Low risk Different groups of participants are balanced in baseline 
characteristics, no statistically significant difference between 
them. Detail in paper and its supplement does not cause any 
concern for other sources of bias not previously mentioned. 
Table 3: Risk of bias table for Davies 2018 (a). 
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Bias domain Authors 
judgement 
Support for judgement 
Random 
sequence 
generation 
(selection bias) 
Low risk Randomisation code made by Vertex Biometrics or a 
'qualified randomisation vendor'. Randomisation 
stratified by ppFEV1 being less than or equal to/greater 
than 70%. 
Allocation 
concealment 
(selection bias) 
Low risk Use of interactive web response system to allocate 
participants to groups. 
Blinding of 
participants and 
personnel 
(performance 
bias) 
Low risk All participants, site personnel and Vertex study team 
were blinded to allocation. Protocol sets out conditions 
when blinding could/should be broken. 
Blinding of 
outcome 
assessment 
(detection bias) 
Unclear 
risk 
All authors were only allowed access to trial data after 
they were unblinded. No mention is made of other 
outcome assessors (e.g. clinicians who weren't authors 
but were involved in seeing participating patients and 
measuring outcomes of interest) and whether there was 
a possibility of them knowing allocated intervention. 
Incomplete 
outcome data 
(attrition bias) 
Low risk All patients who were randomised are accounted for. 
Selective 
reporting 
(reporting bias) 
Unclear 
risk 
States in methods that it would measure 12 lead ECG 
and vital signs, though these may have been measured, 
they are not stated in result or supplement regardless of 
if they were unremarkable or not. 
Other bias Low risk Different groups of participants are balanced in baseline 
characteristics, no statistically significant difference 
between them. Detail in paper and its supplement does 
not cause any concern for other sources of bias not 
previously mentioned. 
Table 4: Risk of bias table for Davies 2018 (b) 
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Bias domain Authors 
judgement 
Support for judgement 
Random 
sequence 
generation 
(selection bias) 
Low risk Randomisation code made by Vertex Biostatistics or a 
'qualified randomisation vendor'. Randomisation 
stratified by FEV1 % predicted (less than or equal to 70% 
versus greater than 70%). 
Allocation 
concealment 
(selection bias) 
Low risk Use of interactive web response system for allocation. 
Blinding of 
participants and 
personnel 
(performance 
bias) 
Low risk All participants, site personnel and Vertex study team 
related to the study were blinded. A clear statement on 
when unblinding is necessary/permitted is provided in 
the protocol. 
Blinding of 
outcome 
assessment 
(detection bias) 
Unclear 
risk 
All authors were only allowed access to study data after 
they were unblinded. No mention is made of other 
outcome assessors (e.g. clinicians who were not authors 
but were involved in seeing participants and measuring 
outcomes of interest) and whether there was a 
possibility of them knowing allocated intervention. 
Incomplete 
outcome data 
(attrition bias) 
Low risk All participants who were randomised are accounted for. 
Selective 
reporting 
(reporting bias) 
Unclear 
risk 
States in methods that it would measure 12-lead ECG 
and vital signs, though these may have been measured, 
they are not stated in results or supplement regardless 
of if they were unremarkable or not. 
Other bias Low risk Different groups of participants are balanced in baseline 
characteristics, no statistically significant difference 
between them. Detail in paper and its supplement does 
not cause any concern for other sources of bias not 
previously mentioned. 
Table 5: Risk of bias table for Keating 2018 
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4.3.4 Effects of interventions 
4.3.4.1 Monotherapy 
Primary outcomes 
1. Survival: 
None of the studies reported any deaths. 
2. Quality of life: 
 
a. Total QoL score 
No studies reported upon this outcome. 
 
b. Different QoL sub-domains 
Data were available for effects lumacaftor and cavosonstat on QoL sub-domains of the 
CFQ-R quality of life score for the immediate time-frame (up to 1 month). No significant 
improvements were seen between intervention and placebo across all domains for both 
drugs and lumacaftor lead to a statistically significant decrease in CFQ-R scores for the role 
domain (25 mg), respiratory (25 mg & 50 mg), eating, health perceptions and treatment 
burden domains (50 mg) (162, 164).  
Horsley reported FDL169 led to a change from baseline at 28 days for the CFQ-R respiratory 
domain. This favoured the 400 mg group (n = 6) compared to placebo, MD 5.09 (95% CI -
2.72 to 12.90); there was no difference between the 600 mg group (n = 6) and placebo, MD 
-4.33 (95% CI -12.01 to 3.35); and favoured the 800 mg group (n = 8) over placebo, MD 8.84 
(95% CI 1.40 to 16.28) (160). 
 
3. Physiological measures of lung function 
a. FEV1 relative change from baseline:  
Data for this were available for lumacaftor, cavosonstat (FEV1 relative change and absolute 
values and FVC) and N6022 (FEV1 relative change). No statistically significant difference was 
observed versus placebo for any of these medications (162-164). 
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b. FEV1 (absolute values) 
Data for this were available for lumacaftor and cavosonstat, which led to no statistically 
significant difference in FEV1 absolute change (162, 164). Data was also available for 
FDL169. This study reported the absolute change from baseline in FEV1 % predicted at day 
28; there was a greater increase in the 400 mg group than placebo, MD 4.68 (95% CI 0.12 to 
9.24) but no difference between the 600 mg group and placebo, MD 2.80 (95% CI -1.82 to 
7.42) or between the 800 mg group and placebo, MD 0.68 (95% CI -3.80 to 5.16) (160).  
c. FVC  
This outcome was reported for Cavosonstat, which led to no statistically significant changes 
in FVC versus placebo (164). 
d. LCI 
Not reported by any study. 
e. Other relevant measures of lung function 
 
Secondary outcomes 
1. Adverse events: 
Lumacaftor- No significant difference was observed between lumacaftor and placebo in the 
number of participants experiencing adverse effects at day 14, and the severity of these 
effects (161, 162). 
Cavosonstat- all adverse events were found to be mild or moderate and there was no 
significant difference between cavosonstat and placebo in the occurrence and severity of 
adverse events (164). 
N6022- no significant difference was reported in the occurrence and severity of adverse 
events between N6022 and placebo (163). 
CPX- no significant difference was reported in the occurrence and severity of adverse 
events between CPX and placebo (165). 
4BPA- No statistically significant difference was reported in the occurrence and severity of 
adverse events between 4BPA and placebo. This was the case for both the pilot and phase 
2 studies of this medication (166, 167). 
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FDL169- This study reported the number of participants experiencing at least one adverse 
event, and the number of 'serious' adverse events, AEs were not categorised under mild, 
moderate or severe. No statistically significant difference was found in the number of 
participants experiencing at least one adverse event between any tested dose level of 
FDL169 and placebo; for the 400 mg group, OR 6.67 (99% CI 0.21 to 207.87); for the 600 mg 
group, OR 0.06 (99% CI 0.00 to 4.00); and for the 800 mg group, OR 21.86 (99% CI 0.34 to 
1419.86). Similarly, there was no statistical difference observed in the occurrence of any 
particular adverse event or of serious adverse events (160).  
2. Hospitalisation:  
No study reported this outcome. 
3. Attendance at school or work: 
No study reported this outcome. 
4. Extra courses of antibiotics: 
a. Time to next course of antibiotics 
Not reported by any study 
b. Total number of courses of antibiotics: 
Lumacaftor- no significant difference between lumacaftor and placebo in the number of 
exacerbations or extra courses of antibiotics needed (161, 162). 
FDL169- From the published abstract for this Phase 1 study, it is unclear whether 
exacerbations were physician or protocol defined. A total of three participants across all 
groups were reported to have had an infective respiratory exacerbation; no participants in 
the 400 mg group, one participant in the 600 mg group, one participant in the 800 mg and 
one participant in the placebo group (160). 
Other studies did not report this outcome. 
5. Sweat chloride (change from baseline) as a measure of CFTR function: 
Lumacaftor: the two studies examining this intervention provided inconsistent findings. The 
first study found no significant decrease in sweat chloride in once daily 25 mg, 50 mg, 100 
mg and 200 mg at 7 days. At day 28, there was a statistically significant decrease in sweat 
chloride in the 100 mg and 200 mg once daily of -6.13mmol/L (95% CI -12.25 to -0.01) and   
-8.21 mmol/L (95% CI -14.30 to - 2.12), respectively (162). The second study found no 
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statistically significant difference between lumacaftor and placebo in change in sweat 
chloride in its test dose of 200 mg at day 21 (161). 
Cavosonstat- No significant difference was found versus placebo in change in sweat 
chloride (164). 
 CPX- No significant difference was found versus placebo in change in sweat chloride (165). 
4BPA- Both the pilot study and phase 2 found no significant difference in sweat chloride 
versus placebo (166, 167). 
FDL169- This study reported the absolute change in sweat chloride (mmol/L) at 28 days. 
There was no difference between the 400 mg group and placebo, MD 2.47 (95% CI -4.47 to 
9.41) or between the 800 mg group and placebo, MD 3.48 (95% CI -3.35 to 10.31), but 
there was a greater drop in sweat chloride in the placebo group than the 600 mg group, MD 
8.07 (95% CI 0.98 to 15.16) (160). 
6. Radiological measures of lung disease: 
Not reported by any study. 
7. Acquisition of respiratory pathogens: 
The only pathogen stated was P. aeruginosa. One study (phase 2 4BPA) stated this 
pathogen as an outcome which they will report upon, however no results for this were 
included (167). 
8. Eradication of respiratory pathogens 
Not reported by any study. 
9. Nutrition & growth 
No parameter for this outcome (e.g. weight, BMI) was reported by any study. 
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4.3.4.2 Dual combination therapy (adapted from first version of review) 
No new dual combination trials were identified by the latest search. Therefore, this 
provides a summary of dual combination results from the previous edition of this review. 
Primary outcomes 
1. Survival: 
No deaths were reported by any of the studies. 
2. Quality of Life: 
a. Total QoL score: 
Lumacaftor-ivacaftor: 
 TRAFFIC & TRANSPORT reported total EuroQol 5 dimension- 3 Level Index at 6 months. No 
statistical difference vs. placebo was observed. No other studies reported total quality of 
life score (170). 
b. QoL sub-domains:  
Lumacaftor-ivacaftor: 
A statistically significant improvement versus placebo in CFQ-R respiratory domain was 
reported at 28 days in the lumacaftor-ivacaftor 600 mg once daily-250 mg twice daily and 
400 mg twice daily-250 mg twice daily (mean difference (MD) 3.32 (95% CI: 1.13 to 5.51) 
and 4.13 (95% CI: 1.94 to 6.31), respectively). At 6 months the statistically significant 
improvement was maintained in the 600 mg group (MD 3.04 (95% CI 0.76 to 5.32)), but not 
in the 400 mg group (MD 2.18 (95% CI -0.11 to 4.47)), but when the results for these doses 
were pooled there was still a statistically significant improvement in CFQ-R at 6 months 
(170).  
At this time point, a statistically significant improvement in the EuroQol 5D-3L visual 
analogue scale domain was reported in both these dose levels, and when pooled (170). 
A study of lumacaftor-ivacaftor in children reported on change CFQ-R respiratory domain at 
day 15 and weeks 4, 16 and 24. Improvements were seen but were not statistically 
significant. 
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Tezacaftor-ivacaftor: 
At 4 weeks, a statistically significant improvement in the CFQ-R respiratory domain was 
seen in one trial (n=510) (MD 5.10 (95% CI 2.99 to 7.21)). This trial also reported a 
statistically significant improvement versus placebo at 24 weeks (MD 5.10 (95% CI 3.20 to 
7.00)) (169). In a second trial (n=18), change in CFQ-R respiratory domain at 4 weeks was 
reported as 6.81 points (P = 0.2451) (100).                                                                                               
3. Physiological measures of lung function: 
a. FEV1 relative change from baseline: 
Lumacaftor-ivacaftor:  
TRAFFIC and TRANSPORT did not report relative FEV1 change at 4 weeks, but did report it at 
6 months, when both dose groups had a statistically significant improvement (600 mg OD: 
MD 5.63 (95% CI 3.80 to 7.47), 400 mg BD: MD 4.77 (95% CI 2.93 to 6.61).  
Tezacaftor-ivacaftor:  
One trial (n=504) found no significant difference versus ivacaftor alone at 4 weeks in 
relative change in FEV1 from baseline (100). Another trial (n=510) found at 24 weeks there 
was a significant improvement in relative change in FEV1 from baseline versus placebo (MD 
6.80 (95% CI 5.30 to 8.30)) (169). 
b. FEV1 (absolute values) 
Lumacaftor-ivacaftor:  
Statistically significant improvements were seen in FEV1 absolute values in TRAFFIC and 
TRANSPORT at day 28 for both the 600 mg OD and 400 mg BD groups (MD 2.32 (95% CI 
1.34 to 3.31) and 2.42 (95% CI 1.43 to 3.40), respectively (170).  Another study reported 
improvements in FEV1 absolute values that were not statistically significant at day 21 (161). 
Tezacaftor-ivacaftor:  
Both tezacaftor studies reported a statistically significant improvement in FEV1 absolute 
values at 4 weeks (100, 169). 
c. FVC 
Not reported by any of the dual combination studies. 
 
63 
 
d. LCI 
The paediatric lumacaftor-ivacaftor study also reported a statistically significant decrease 
versus placebo in lung clearance index 2.5 (LCI2.5- the amount of times a person’s total lung 
volume turns over in their lungs in order for the concentration of tracer to reach 2.5% of its 
starting concentration). The MD was -1.10 (95% CI -1.40 to -0.80) which in this case 
indicated a desirable change (168). 
e. Other measures of lung function 
No included trial reported upon outcomes in this category. 
Secondary outcomes 
1. Adverse events: 
Lumacaftor-ivacaftor:  
TRAFFIC & TRANSPORT found a statistically significant increase in shortness of breath in the 
lumacaftor 600 mg OD- ivacaftor 250 mg BD group versus placebo (OR 2.05 (99% CI 1.10 to 
3.83)), this significance was also maintained when the 600 mg OD and 400 mg BD results 
were pooled (OR 1.90 (99% CI 1.08 to 3.35)). They also found cough to be statistically 
significantly lower in the lumacaftor 400 mg BD- ivacaftor 250 mg OD group versus placebo 
(OR 0.58 (99% CI 0.39 to 0.88)), significance was also maintained when pooled with the 600 
mg OD group (OR 0.65 (99% CI 0.46 to 0.92)) (170).  
A statistically significant mean increase in blood pressure over the 120 week study period of 
the PROGRESS extension to TRAFFIC & TRANSPORT was observed with an increase in 
systolic blood pressure of 5.1 (SE: 1.5) mm Hg and an increase in diastolic blood pressure of 
4.1 (SE: 1.2) mm Hg (n=80) (171). Aside from what is mentioned here, none of the trials 
found any other statistically significant differences in the occurrence or severity of adverse 
events across a range of doses of lumacaftor-ivacaftor versus placebo (161, 168, 170, 171). 
Tezacaftor-ivacaftor: 
No statistically significant difference was found versus placebo or control (ivacaftor alone) 
in the occurrence or severity of adverse events by either of the included trials for this 
intervention (100, 169). 
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2. Hospitalisation: 
Lumacaftor-ivacaftor:  
The lumacaftor 600 mg OD group had a rate of events leading to hospitalisation 39% lower 
than placebo (0.45 versus 0.27, respectively, P=0.003). The 400 mg BD group had a rate of 
events leading to hospitalisation of 0.18, this corresponds to a 61% lower rate than placebo 
(P<0.001) (170).  
Tezacaftor-ivacaftor:  
One trial reports the occurrence of pulmonary exacerbations which require hospitalisation. 
This was lower in the intervention group than in the placebo group (0.29 vs. 0.54 events per 
year, corresponding to a rate ratio of 0.53 (95% CI 0.34 to 0.82) (168). 
3. Attendance at school or work: 
Not reported by any included study. 
4. Extra courses of antibiotics: 
Lumacaftor-ivacaftor: 
TRAFFIC & TRANSPORT found both the 600 mg OD and 400 mg BD groups to have a 
statistically significant increase in the time to first pulmonary exacerbation (hazard ratio: 
600 mg OD group: 0.70 (95% CI 0.57 to 0.87), 400 mg BD group: 0.61 (95% CI 0.49 to 0.76). 
Both doses also led to a statistically significant decrease in the rate of exacerbations when 
compared to placebo (rate ratio: 600 mg OD group: 0.70 (95% CI 0.57 to 0.87), 400 mg BD 
group: 0.61 (95% CI 0.49 to 0.76). TRAFFIC & TRANSPORT also led to a statistically 
significant decrease in the total number of pulmonary exacerbations requiring antibiotics 
over 48 weeks (odds ratio: 0.66 (99% CI 0.45 to 0.97) and 0.57 (99% CI 0.39 to 0.84), 
respectively (170). But another study (n=62) found no significant difference between 
intervention and placebo in the number of exacerbations reported at day 21 (161). The 
paediatric study also found no statistically significant difference in the number of 
pulmonary exacerbations (168). 
Tezacaftor-ivacaftor: 
One trial reported tezacaftor-ivacaftor led to a statistically significantly longer time to first 
pulmonary exacerbation versus placebo (hazard ratio: 0.64 (95% CI 0.46 to 0.89)) (169). 
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5. Sweat chloride (change from baseline) as a measure of CFTR function: 
Lumacaftor-ivacaftor: 
One study found that at day 21 (after 14 days of lumacaftor monotherapy followed by 6 
days of lumacaftor-ivacaftor combination therapy, there was a statistically significant 
decrease versus placebo in the concentration of sweat chloride in both the lumacaftor 200 
mg OD- ivacaftor 150 mg BD and the lumacaftor 200 mg OD-ivacaftor 250 mg BD groups: 
MD -5.00 mmol/L (95% CI -11.60 to 1.60) and -10.90 mmol/L (95% CI -17.60 to -4.20), 
respectively (161). The paediatric trial also found lumacaftor-ivacaftor to have a statistically 
significantly greater reduction in sweat chloride when compared to placebo at 4 weeks (MD 
-20.80 mmol/L (95% CI -23.40 to -18.20)) (168). 
Tezacaftor-ivacaftor: 
2 studies found a statistically significantly greater reduction in sweat chloride concentration 
versus placebo at 4 weeks. Their pooled MD was -9.24 mmol/L (95% CI -11.12 to -7.35) 
(100, 169). Of these two studies, one of them carried on to 24 weeks, where it found there 
to still be a statistically significantly greater decrease in sweat chloride concentration (MD -
10.10 mmol/L (95% CI -11.40 to -8.80)) (169). 
 
6. Radiological measures of lung disease 
7. Acquisition of respiratory pathogens 
8. Eradication of respiratory pathogens 
None of outcomes 6,7 or 8 were reported by any included study. 
9. Nutrition and growth 
Lumacaftor-ivacaftor: 
TRAFFIC & TRANSPORT showed a statistically significantly greater absolute weight gain at 6 
months when compared to placebo for both the 600 mg OD and 400 mg BD groups (MD: 
0.80 kg (95% CI 0.42 to 1.18) and 0.65 kg (95% CI 0.27 to 1.03), respectively). At 6 months 
both groups also had a statistically significantly greater absolute gain in BMI (MD: 0.29 (95% 
CI 0.16 to 0.43) and 0.25 (95% CI 0.12 to 0.39), respectively (170). The paediatric trial did 
not report weight, despite stating it as an outcome of interest; however, it did report BMI 
at 6 months by absolute change from baseline BMI and absolute change in BMI-for-age z 
score. Its reported changes in BMI were not statistically significant (168). 
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Tezacaftor-ivacaftor: 
One of the tezacaftor trials reported on BMI, however it did not find a statistically 
significant difference between intervention and placebo at either 4 weeks or 24 weeks 
(169). 
 
Summarising monotherapy & dual combination therapy- adaptations from previous 
review plus addition of new data. 
The correctors which have so far been tested in monotherapy have not shown significant 
improvements versus placebo in the stated outcomes of interest in the trials and the 
Cochrane systematic review. When used in dual combination with a potentiator, small but 
statistically significant improvements in several important outcomes were seen, but 
notable side effects of transient increased shortness of breath and long-term blood 
pressure increases were also found to be statistically significant. 
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4.3.4.3 Triple combination therapy (new data) 
Included studies 
The newly included triple therapy studies are summarised in the below table. 
Trial Intervention Control Target group Number of 
patients 
Duration 
Davies 
2018a 
VX-659-
tezacaftor-
ivacaftor or 
VX-659-
tezacaftor-
VX-561 
Placebo-
tezacaftor-
ivacaftor or 
triple placebo 
Adults with CF 
with either 
F508del/minimal 
function or 
F508del/F508del 
genotypes 
12 
(9 to 
intervention, 
3 to control) 
2 weeks 
Davies 
2018b 
VX-659-
tezacaftor-
ivacaftor 
Triple placebo Adults with CF 
with 
F508del/minimal 
function 
genotypes. 
117 
(90 to 
intervention, 
27 to 
control) 
4 weeks 
Keating 
2018 
VX-445-
tezacaftor-
ivacaftor 
Placebo-
tezacaftor-
ivacaftor (for 
F508del/F508del 
or triple placebo 
for 
F508del/minimal 
function. 
Adults with CF 
with 
F508del/minimal 
function of 
F508del/F508del 
genotypes. 
123 
(96 to 
intervention 
27 to 
control) 
4 weeks 
Table 6: Table summarising the methodologies of the newly included triple therapy studies. 
Participants 
Three of the new studies (Davies (a) & (b), Keating) recruited people with CF who had one 
copy of the F508del CFTR variant and one copy of a minimal function (MF) variant, which 
means it is not responsive to ivacaftor alone. Davies b and Keating also recruited another 
group of participants with two copies of F508del (151, 152). All of the new studies recruited 
adults only. 
Interventions 
The three new triple combination studies examined either VX-659-tezacaftor-ivacaftor 
versus placebo (Davies a & Davies b) or active control of tezacaftor-ivacaftor (Davies b) or 
VX-445-tezacaftor-ivacaftor versus placebo of active control of tezacaftor-ivacaftor 
(Keating). 
Outcomes 
All of the new studies reported lung function by means of FEV1. They also all reported 
quality of life using the CFQ-R respiratory domain, as well as adverse effects and change in 
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sweat chloride concentration. Davies (a & b) and Keating reported on pulmonary 
exacerbations. None of the studies reported specifically on hospitalisation rates (151, 152). 
Funding sources 
Pharmaceutical companies funded all 3 of these new studies. 
 
Correctors plus potentiators (triple combination therapy) 
A single two-week Phase 1 study (n = 12) compared VX-659 120 mg and ivacaftor 150 mg 
every 12 hours plus tezacaftor 100 mg once daily versus equivalent placebo in participants 
whose genotype was F508del/MF variant (Davies 2018a) (152). 
One four-week Phase 2 study compared three doses of VX-659 with tezacaftor and 
ivacaftor versus a single placebo group (n = 10) in participants with an F508del/MF 
genotype (n = 53) as follows:  
VX-659 80 mg and tezacaftor 100 mg once daily plus ivacaftor 150 mg twice daily (n = 11); 
VX-659 240 mg and tezacaftor 100 mg once daily plus ivacaftor 150 mg twice daily (n = 20); 
VX-659 400 mg and tezacaftor 100 mg once daily plus ivacaftor 150 mg twice daily (n = 22).  
These groups taking one of the doses had a four-day washout period taking tezacaftor-
ivacaftor only (same doses). This Phase 2 study also included a group to test once daily VX-
659 400 mg plus tezacaftor 100 mg plus VX-561 (deuterated ivacaftor) 150 mg versus 
placebo in another group of participants with an F508del/MF variant genotype (n = 25) for 
four weeks. In another arm of the study, 29 participants who were homozygous for F508del 
were randomised to either VX-659 400 mg plus tezacaftor 100 mg once daily plus ivacaftor 
150 mg twice daily (n = 18) or to placebo plus tezacaftor 100 mg once daily plus ivacaftor 
150 mg twice daily (this dual therapy combination is currently considered the standard of 
care for people with this genotype) (n = 11). This cohort (n = 29) had a four-week run-in 
period taking the same dose of tezacaftor-ivacaftor only before starting the triple therapy 
combination for another four weeks. Once the intervention period was over, these 
participants had a further four-week washout period  where they reverted to the same 
dose of tezacaftor-ivacaftor as a dual combination (Davies 2018b) (152). 
A different Phase 2 study evaluated three different doses of VX-445 versus placebo (n = 12) 
in participants with F508del/MF for a four week period, followed by a washout period of 
tezacaftor plus ivacaftor or dual placebo lasting one week. The intervention doses were: 
69 
 
VX-445 50 mg and tezacaftor 100 mg once daily plus ivacaftor 150 mg twice daily (n = 10); 
VX-445 100 mg and tezacaftor 100 mg once daily plus ivacaftor 150 mg twice daily (n = 14); 
and VX-445 200 mg and tezacaftor 200 mg once daily plus ivacaftor 150 mg twice daily (n = 
21). This same trial also compared once daily VX-445 200 mg plus tezacaftor 100 mg plus 
VX-561 150 mg to triple placebo in another group of participants with a F508del/MF 
genotype (n = 29); these participants did not have a run-in period or a washout period. In 
the same study, another group of participants homozygous for F508del (n = 28) had a four-
week run-in of once daily tezacaftor 100 mg plus ivacaftor 150 mg, followed by the 
intervention period of once daily VX-445 200 mg or equivalent placebo while continuing the 
same doses of tezacaftor and ivacaftor; this was then followed with a washout period 
where all participants took just tezacaftor and ivacaftor at the previous doses for a further 
four weeks (Keating 2018) (151). 
 
 
Primary outcomes 
1. Survival:  
No deaths reported by any of the triple therapy trials. 
2. QoL: 
a. Total QoL score: Not reported by any of these studies 
 
b. QoL sub-domains: 
The two phase 2 studies reported on CFQ-R respiratory domain: 
 
VX-659 plus tezacaftor plus ivacaftor 
Participants with F508del/MF: 
One study (n = 117) reported on the absolute change in the CFQ-R respiratory 
domain following four weeks of treatment (Davies 2018b). For the 80 mg dose 
(n = 11), the change in score was statistically significant in favour of the 
intervention versus placebo, MD 10.00 (95% CI 0.29 to 19.71). No significant 
difference was observed for the 240 mg group (n = 20), MD 4.00 (95% CI -4.70 
to 12.70) or the 400 mg group (n = 22), MD 7.90 (95% CI -0.58 to 16.38) (152). 
 
Participants with F508del/F508del: 
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One study reported a statistically significant improvement in the respiratory 
domain of CFQ-R at the 400 mg dose level of VX-659 versus active control of 
placebo-tezacaftor-ivacaftor (n = 10) (Davies 2018b), MD 18.10 (95% CI 10.85 
to 25.35) (152).  
 
VX-659 plus tezacaftor plus VX-561 
One study tested this regimen in another group of participants with 
F508del/MF (Davies 2018b). The only dose of VX-659 tested in this group was 
400 mg (n = 19). A statistically significant improvement versus placebo in the 
respiratory domain was observed, MD: 20.3 (95% CI 7.1 to 33.6) (152). 
 
VX-445 plus tezacaftor plus ivacaftor 
Participants with F508del/MF: 
In one study (Keating 2018), VX-445 led to a statistically significant 
improvement against placebo in the respiratory domain of CFQ-R for the 50 mg 
dose (n = 10), MD 17.20 (95% CI 4.44 to 29.96), the 100 mg dose (n = 22), MD 
14.50 (95% CI 3.72 to 25.28) and for the 200 mg dose (n = 21), MD 21.30 (95% 
CI 10.52 to 32.08) (151). 
 
Participants with F508del/F508del: 
The study conducted by Keating reported a statistically significant improvement 
in the CFQ-R respiratory domain for the 200 mg group (n = 21) versus the 
placebo-tezacaftor-ivacaftor group (n = 7), MD 19.30 (95% CI 8.34 to 30.26) 
(151). 
 
VX-445 plus tezacaftor plus VX-561 
This regimen was tested in another group of F508del/MF participants, but the 
only dose tested was VX-445 200 mg (n = 21). A statistically significant 
improvement in the respiratory domain of CFQ-R at 4 weeks was observed 
when compared to placebo, MD 12.80 (95% CI 0.93 to 24.67) (151). 
 
No triple therapy trial reported on quality of life beyond the 4-week study 
period of the trials. 
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3. Physiological measures of lung function: 
 
a.  FEV1 (relative change from baseline) 
 
i. Immediate term (up to and including one month) 
Two trials reported on this outcome at the four week time point (Davies 2018b; 
Keating 2018). 
 
VX-659 plus tezacaftor plus ivacaftor 
Participants with F508del/MF: 
One study reported a statistically significant improvement favouring the test 
intervention against placebo at the 80 mg dose level (n = 11), MD 18.36 (95% CI 
3.63 to 33.09), the 240 mg dose level (n = 20), MD 20.17 (95% CI 8.73 to 31.61) 
and also the 400 mg dose level (n = 22), MD 23.85 (95% CI 14.52 to 33.18) 
(152). 
 
Participants with F508del/F508del: 
One study reported a statistically significant difference in the relative change in 
FEV1 % predicted in the 400 mg group (n = 18) when compared with placebo-
tezacaftor-ivacaftor (n = 11), MD 15.99 (95% CI 8.61 to 23.37) (152). 
 
VX-659 plus tezacaftor plus VX-561 
 
Participants with F508del/MF: 
This regimen was tested with a single dose level of VX-659 400 mg in this group 
of participants. It led to a statistically significant improvement in the relative 
change from baseline in FEV1 against placebo (n = 6), MD 33.05 (95% CI 22.05 
to 44.05) (152). 
 
VX-445 plus tezacaftor plus ivacaftor 
Participants with F508del/MF: 
The test intervention led to statistically significant improvements against 
placebo at each included dose level of VX-445: at 50 mg (n = 10), MD 19.0 (95% 
CI 7.08 to 30.92); 100 mg (n = 22), MD 13.5 (95% CI 3.28 to 23.72); and 200 mg 
(n = 21), MD 25.90 (95% CI 15.57 to 36.23) (151). 
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Participants with F508del/F508del: 
In this group of people with CF with this genotype, one study reported a 
statistically significant improvement in relative change from baseline in FEV1 
percent predicted in favour of the test intervention (200 mg dose) when 
compared against placebo-tezacaftor-ivacaftor (n = 7), MD 17.80 (95% CI 6.66 
to 28.94) (151). 
 
VX-445 plus tezacaftor plus VX-561 
Participants with F508del/MF: 
The only dose level of VX-445 tested in this group was 200 mg, the study 
reports a statistically significant improvement for the test intervention group 
against placebo (n = 8), MD 18.30 (95% CI 7.64 to 28.96) (151). 
 
ii. Short term (over one month and up to and including six months) 
 
None of the triple therapy trials reported for time points longer than one 
month. 
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b. FEV1 absolute values 
All three triple combination studies reported on absolute FEV1 values; two studies 
reported the absolute change in L (Davies 2018b; Keating 2018) and one study 
reported the absolute change in % predicted (Davies 2018a). 
 
i. Immediate term (up to and including one month): 
 
VX-659 plus tezacaftor plus ivacaftor 
Participants with F508del/MF: 
A statistically significant improvement was seen in the absolute change in FEV1 (L) 
with the intervention regimen versus placebo for the 80 mg dose (n = 11), MD 0.37 
L (95% CI 0.15 to 0.59), for the 240 mg (n = 20), MD 0.42 L (95% CI 0.20 to 0.64), 
and for the 400 mg dose (n = 22) MD 0.52 L (95% CI 0.34 to 0.70) (152). The Davies 
(a) study reporting the absolute change in FEV1 % predicted only looked at a 
treatment regimen using VX-659 120 mg twice per day in participants with the 
genotype F508del/MF and found that the intervention significantly improved FEV1 
% predicted compared to placebo (n=3), MD 10.00 (95% C: 3.04 to 16.96) (152). 
 
Participants with F508del/F508del: 
One study reported the absolute change in FEV1 (L) (Davies 2018b). Only a dose of 
VX-659 400 mg was tested in this population and the study found a statistically 
significant improvement in favour of the intervention compared to the control 
group (n = 11), MD 0.35 L (95% CI 0.19 to 0.51) (152). 
 
VX-659 plus tezacaftor plus VX-561 
In this group of participants, all of whom had a F508del/MF genotype, only a dose 
of VX-659 400 mg was tested and showed a statistically significant improvement in 
favour of the intervention compared to placebo (n = 6), MD 0.68 L (95% CI 0.45 to 
0.91) (152). 
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VX-445 plus tezacaftor plus ivacaftor 
Participants with F508del/MF: 
This triple therapy combination led to statistically significant improvements at all 
doses of the test intervention compared to placebo: 50 mg (n = 10) MD 0.46 L (95% 
CI0.19, 0.73); 100 mg group (n = 22), MD 0.38 L (95% CI 0.20 to 0.56); and 200 mg 
group (n = 21), MD 0.57 L (95% CI 0.36 to 0.78) (151). 
 
Participants with F508del/F508del: 
Only VX-445 200 mg was tested in this group (n = 21). Results showed a statistically 
significant improvement in absolute change in FEV1 (Litres) versus placebo-
tezacaftor-ivacaftor (n = 7), MD 0.46 L (95% CI 0.26 to 0.66) (151). 
 
VX-445 plus tezacaftor plus VX-561 
Participants with F508del/MF: 
Only a dose of VX-445 200 mg was tested in this group and results showed a 
statistically significant improvement in the absolute change in FEV1 (L) versus 
placebo (n = 8), MD 0.44 L (95% CI 0.25 to 0.63) (151). 
 
 
c. FVC (absolute values and change from baseline) 
Not reported by any of the included triple therapy studies. 
 
d. LCI 
Not reported by any of the included triple therapy studies. 
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Secondary outcomes 
1. Adverse events 
Adverse events were reported by all of the studies examining triple combination 
therapies. All three of the studies reported adverse events as according to mild, 
moderate or severe; they also recorded the "most common adverse events" which 
they defined as occurring in at least 5% participants. We have set CIs for adverse 
events at 99%, as per "measure of treatment effect" in this review's methodology. 
 
VX-659 plus tezacaftor plus ivacaftor versus placebo 
There was no significant difference in the number of participants experiencing at 
least one adverse event between the test intervention and placebo at any dose or 
for any genotype. For each VX-659 dose level, the ORs and their corresponding 99% 
CIs were as follows: 80 mg (n = 11), OR 1.11 (99% CI 0.02 to 51.19); 120 mg twice 
daily (n = 9), OR 31.67 (99% CI 0.32 to 3111.29); 240 mg (n = 20), OR 0.33 (99% CI 
0.02 to 6.85); 400 mg (for participants with F508del/MF) (n= 22), OR 0.38 (99% CI 
0.02 to 7.70); 400 mg (for participants with F508del/F508del) (n = 18 ), OR 1.25 
(99% CI 0.05 to 34.62) All doses are once daily except for 120 mg, which was taken 
twice daily in the Phase 1 study (152). 
 
VX-659 plus tezacaftor plus VX-561 versus placebo 
For this comparison, there was no significant difference in adverse events between 
the test intervention and placebo (n = 6), OR 0.95 (99% CI 0.01 to 74.78) (152). 
 
VX-445 plus tezacaftor plus ivacaftor versus placebo 
No statistically significant differences in the number of adverse events were 
observed between the intervention and placebo groups. In the 50 mg cohort, every 
participant in both the intervention and placebo groups had an adverse event, 
therefore an OR was not estimable. For every other dose, their corresponding ORs 
and CIs are: 100 mg (n = 22), OR 0.57 (99% CI 0.01 to 42.46); 200 mg (for 
participants with F508del/MF) (n = 21), OR 0.21 (99% CI 0.00 to 11.62); and for 200 
mg (for participants with F508del/F508del), (n = 21), OR 3.80 (99% CI: 0.21 to 
67.89) (151). 
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VX-445 plus tezacaftor plus VX-561 versus placebo 
No statistically significant difference in the number of adverse events were 
observed between the intervention (n= 21) and placebo (n = 8) groups, OR 1.36 
(99% CI 0.05 to 38.84) (151). 
 
a. Mild (therapy does not need to be discontinued) 
 
We could not accurately record the number of mild adverse events occurring in any 
of the triple therapy studies since they record the number of participants 
experiencing at least one adverse event, by the maximum severity, meaning that a 
participant may have had numerous 'mild' adverse events and a single moderate or 
severe event, but we would only be aware of the single most severe event (151, 
152). 
 
b. Moderate (therapy is discontinued, and the adverse effect ceases) 
 
Our definition of a moderate adverse effect differed to that used in the studies, 
however the studies also reported the number of adverse events which led to 
discontinuation of therapy. We therefore used this number to record the number 
of moderate adverse events according to our definition. 
 
VX-659 plus tezacaftor plus ivacaftor 
No participants in either the intervention or placebo groups were recorded as 
having a moderate adverse event in any of the dose groups (VX-659 80 mg, VX-659 
120 mg 2 x daily group, VX-659 400 mg for participants with F508del/MF and with 
F508del/F508del), meaning an OR was not calculable. 
For the VX-659 240 mg group, there was no statistically significant difference in the 
number of moderate adverse events between the intervention (n = 20) and placebo 
groups (n = 10), OR 1.62 (99% CI 0.02 to 121.50) (152). 
 
VX-659 plus tezacaftor plus VX-561 
No statistically significant difference was observed in the number of moderate 
adverse events between the intervention (n = 19) and placebo groups (n = 6) in this 
treatment regimen group, OR 1.86 (99% CI 0.03 to 119.25) (152). 
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VX-445 plus tezacaftor plus ivacaftor 
No participants in either the In the VX-445 50 mg or the VX-445 100 mg groups or 
the placebo groups were recorded as having a moderate adverse event, meaning 
an OR was not calculable for the groups taking this dose (151). 
 
There were no statistically significant differences in the number of moderate 
adverse events experienced by the intervention and placebo groups across all 
doses and genotypes: VX-445 200 mg (participants with F508del/MF) (n = 21), OR 
0.31 (99% CI 0.04 to 2.28); and VX-445 200 mg (participants with F508del/F508del) 
(n = 21) OR 1.54 (99% CI 0.1 to 17.8) (151). 
 
VX-445 plus tezacaftor plus VX-561 
No participants in either the intervention or placebo groups experienced a 
moderate adverse effect, meaning an OR was not calculable for this group (151). 
 
c. Severe (life-threatening or debilitating, or which persists even after stopping 
treatment) 
 
Our definition of severe adverse events was equivalent to the studies' definition of 
a serious adverse event; therefore we counted the number of participants 
reporting serious adverse events.  
 
VX-659 plus tezacaftor plus ivacaftor 
Severe adverse events occurred at every dose level and for both F508del/F508del 
and F508del/MF participants. The severe events occurred in the intervention and 
placebo groups and there was no statistically significant difference between 
intervention and placebo. Respective ORs and 99% CIs for each group were: VX-659 
80 mg (n = 11), OR 0.23 (99% CI 0.01 to 5.92); VX-659 120 mg twice daily (n = 9), OR 
2.33 (99% CI 0.03 to 176.29); VX-659 240 mg (n = 20), OR 0.58 (99% CI 0.06 to 5.75); 
VX-659 400 mg (participants with F508del/MF) (n = 22), OR 0.11 (99% CI 0.00 to 
2.67); VX-659 400 mg (participants with F508del/F508del) (n = 18), OR 0.26 (99% CI 
0.01 to 7.39) (152). 
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VX-659 plus tezacaftor plus VX-561 
No statistical difference was found between the intervention (n=19) and placebo 
(n=6) groups for the number of severe adverse effects for this group OR: 0.12 (99% 
CI 0.01 to 2.04) (152). 
 
 
VX-445 plus tezacaftor plus ivacaftor 
No statistically significant differences were observed between the intervention and 
placebo groups, across all doses and genotypes. Results for each of the dose and 
genotype groups are as follows: VX-445 50 mg (n = 10), OR 0.56 (99% CI 0.02 to 
16.15); VX-445 100 mg (n = 22), OR 0.50 (99% CI 0.03 to 7.92); VX-445 200 mg 
(participants with F508del/MF) (n = 21), OR 0.10 (99% CI 0.00 to 5.93); VX-445 200 
mg (participants with F508del/F508del) (n = 21), OR 0.10 (99% CI 0.00 to 7.90) 
(151). 
 
VX-445 plus tezacaftor plus VX-561 
None of the 21 participants in the intervention group and one out of eight 
participants in the placebo group experienced a severe adverse event. There was 
no statistically significant difference observed between the groups (total n = 29), 
OR 0.12 (99% CI 0.00 to 8.97) (151). 
 
2. Hospitalisation 
Not reported by any of the included triple therapy studies. 
 
 
3. Attendance at work or school 
Not reported by any of the included triple therapy studies. 
 
 
4. Extra courses of antibiotics 
 
a. Time-to the next course of antibiotics 
Not reported by any of the included triple therapy studies. 
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b. Total number of courses of antibiotics 
Like previously, under this outcome, we will report on the occurrence of 
infective pulmonary exacerbations. 
 
VX-659 plus tezacaftor plus ivacaftor 
Davies' phase 1 study found that in the 120 mg twice daily group, two out of 
nine participants in the test group and none of the three participants in the 
placebo group had an infective pulmonary exacerbation, OR 2.33 (95% CI 0.03 
to 176.29) (152). 
 
Davies' phase 2 study found that in the 80 mg group, three out of 11 
participants in the intervention group and two out of 10 participants in the 
placebo group had an exacerbation, OR 1.50 (95% CI 0.10 to 21.90); in the 240 
mg once daily group, three out of 20 participants in the intervention group and 
two out of 10 in the placebo group had an exacerbation, OR 0.71 (95% CI 0.05 
to 9.48); in the 400 mg F508del/MF group, four out of 22 participants in the 
intervention group and two out of 10 in the placebo group had an 
exacerbation, OR 0.89 (95% CI 0.07 to 10.67); in the 400 mg F508del/F508del 
group five out of 18 participants in the intervention group and three out of 11 
in the placebo group had an exacerbation, OR 1.03 (95% CI 0.11 to 9.34) (152). 
 
VX-659 plus tezacaftor plus VX-561 
Davies found that two out of 19 participants in the intervention group and 
three out of six participants in the placebo group had an exacerbation, OR 0.12 
(95% CI 0.01 to 2.04) (152). 
 
VX-445 plus tezacaftor plus ivacaftor 
Keating found that in the 50 mg group, three out of 10 participants in the 
intervention group and four out of 12 participants in the placebo group had an 
infective pulmonary exacerbation, OR 0.86 (95% CI 0.08 to 9.23). In the 100 mg 
group five out of 22 participants in the intervention group and three out of 12 
participants on placebo had an exacerbation, OR 0.59 (95% CI 0.08 to 4.57). In 
the 200 mg F508del/MF group, two out of 21 on active treatment regimen and 
four out of 12 on placebo had an exacerbation, OR 0.21 (95% CI 0.02 to 2.52). 
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In the 200 mg F508del/F508del group, five out of 21 and one out of seven 
participants in the intervention and placebo groups, respectively, had an 
exacerbation, OR 1.88 (95% CI 0.09 to 40.77). It was not clear whether the 
exacerbations were protocol-defined or physician-defined (151). 
 
VX-445 plus tezacaftor plus VX-561 
Keating found that in this group, three out of 21 of those on the active regimen 
and four out of eight participants on placebo had an infective respiratory 
exacerbation during the study, OR 0.17 (95% CI 0.01 to 1.89) (151). 
 
5. Sweat chloride (change from baseline) as a measure of CFTR function 
VX-659 plus tezacaftor plus ivacaftor 
One phase 1 study found the 120 mg twice-daily active intervention (n = 9) to 
reduce sweat chloride by 41.6 mmol/L and placebo (n = 3) to reduce sweat chloride 
by 11.0 mmol/L, MD -30.60 mmol/L (95% CI -46.38 to -14.82) (152). 
 
A phase 2 study found that all active intervention groups showed a significant 
difference in the change in sweat chloride compared to placebo. The placebo group 
(n = 10) experienced an increase in sweat chloride by 2.9 mmol/L, whereas the 80 
mg intervention group (n = 11) reduced sweat chloride by 45.70 mmol/L, MD -
48.60 mmol/L (95% CI -60.94 to -36.26); the 240 mg intervention group (n = 20) 
reduced sweat chloride by 43.8 mmol/L, MD: -46.70 mmol/L (95% CI -57.91 to -
35.49); the 400 mg F508del/MF intervention group (n = 22) reduced sweat chloride 
by 51.4 mmol/L, MD -54.30 mmol/L (95% CI -65.28 to -43.32); and the 400 mg 
F508del/F508del group (n = 18) had a sweat chloride reduction of 42.2 mmol/L, MD 
-45.20 mmol/L (95% CI -52.18 to -38.22) (152). 
 
VX-659 plus ivacaftor plus VX-561 
In this group, Davies found placebo (n = 6) to decrease sweat chloride by 1.3 
mmol/L, and the intervention group (n = 19) showed a reduction of 38.1 mmol/L, 
MD -36.80 mmol/L (95% CI -48.74 to -24.86) (152). 
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VX-445 plus tezacaftor plus ivacaftor 
The Keating study found that all active intervention groups in this comparison 
showed a significant difference in the change in sweat chloride compared to 
placebo. The placebo group for the ascending dose F508del/MF groups (n = 12) 
showed a decrease in sweat chloride of 2.2 mmol/L and the 50 mg group (n = 10) 
showed a decrease of 38.2 mmol/L, MD -36.00 mmol/L (95% CI -47.23 to -24.77); 
the 100 mg group (n = 22) showed a decrease of 33.2 mmol/L, MD -31.00 mmol/L 
(95% CI -40.41 to -21.59); the 200 mg F508del/MF group (n = 21) showed a 
decrease of 39.1 mmol/L, MD -36.90 mmol/L (95% CI -46.43 to -27.37); and the 200 
mg F508del/F508del group (n = 21) showed a decrease of 39.6 mmol/L, MD -40.40 
mmol/L (95% CI -51.46 to -29.34) (151). 
 
VX-445 plus tezacaftor plus VX-561 
Keating found that the placebo group (n = 8) for this group showed an increase of 
1.0 mmol/L and the intervention group (n = 21) showed a decrease of 33.6 mmol/L, 
MD -34.60 mmol/L (95% CI -45.15 to -24.05) (151). 
 
6. Radiological measures of lung disease 
 
7. Acquisition of respiratory pathogens 
 
8. Eradication of respiratory pathogens 
 
9. Nutrition and growth 
 
Outcomes 6, 7, 8 & 9 were not reported by any of the included triple therapy 
studies. 
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Pooled efficacy data for triple therapy combinations: 
We pooled efficacy data for the varying doses of VX-659 and VX-445, along with data for 
their combinations with VX-561 (which was considered a similar enough intervention to 
normal ivacaftor to be included in this meta-analysis, were combined together to examine 
the overall efficacy of triple therapy combination options. Only data examining triple 
therapy options in people with CF with the F508del/MF genotypes were included, as they 
were who the majority of data was collected on and we did not want to introduce genotype 
as a confounder by including those with F508del/F508del genotypes. This pooled data 
included adults only, as no children were included as part of the enrolled study population. 
We did not pool adverse event data due to the complexity of their measurement and 
reporting and decided that a narrative description of these results in the individual sections 
above would provide a better illustration of adverse event data. 
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Quality of life 
Overall, triple therapy (n = 146) significantly improved the CFQ-R respiratory domain score 
compared to placebo (n = 80), MD 12.03 (95% CI 8.36 to 15.71). Improvements were 
statistically significant across all combinations and dose levels except for the VX-659 240 
mg and 400 mg- tezacaftor- ivacaftor groups (151, 152). 
 
Figure 6: Forest plot showing change from baseline in CFQ-R respiratory domain for all dose combinations in 
participants with F508del/MF genotypes, plus overall pooled result from these data. 
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FEV1 % predicted relative change from baseline 
Overall, triple therapy combinations (n = 146) were found to have a statistically significantly 
improvement in the relative change from baseline in percent predicted FEV1 versus placebo 
(n = 80), MD 22.78% (95% CI 18.92 to 26.63). Improvements were statistically significant for 
all included combinations and dose levels (151, 152). 
 
Figure 7: Forest plot showing relative change in percent predicted  FEV1 for all dose combinations in participants 
with F508del/MF genotypes, plus overall pooled result from these data. 
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FEV1 absolute change from baseline 
Overall, triple therapy (n = 146) was found to have a statistically significant improvement in 
absolute change in FEV1 versus placebo (n = 80), MD: 0.47 L (95% CI 0.40 to 0.55). 
Improvements were statistically significant for all included combinations and dose levels 
(151, 152). 
 
Figure 8: Forest plot showing absolute change in FEV1  for all dose combinations in participants with F508del/MF 
genotypes, plus overall pooled result from these data. 
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Sweat chloride absolute change from baseline 
Overall, triple therapy (n = 146) was found to significantly improve the absolute change in 
sweat chloride from baseline versus placebo (n = 80), MD -39.34 mmol/L (95% CI -43.04 to -
35.65). Improvements were statistically significant for all included combinations and dose 
levels (151, 152). 
 
Figure 9: Forest plot showing change from baseline in sweat chloride for all dose combinations in participants 
with F508del/MF genotypes, plus overall pooled result from these data. 
 
We note the I2 statistic is noticeably larger for this forest plot when compared to the others, 
despite the graph appearing to be less heterogeneous than others. Following discussion 
with the team statistician, it is thought that this I2 statistic value is due to the differences in 
the magnitude of the changes in sweat chloride for each regimen & dose. It should also be 
noted that as a result of differing magnitude of changes, the x axes on each forest plot 
differ in scale. This can make heterogeneity more difficult to compare between the forest 
plots of the different measures of outcomes. 
87 
 
4.4 Discussion for Cochrane systematic review 
F508del, a class II variant is prevalent, especially in those who descend from Northern 
European ancestry. 80-90% of people with CF have at least one copy of F508del (13). A 
therapy which effectively corrects the folding defect of class II variants could have a 
significant impact on the treatment of many people with CF. 
4.4.1 Summary of main results 
This latest update identified 4 new studies evaluating correctors in people with CF who 
have at least one F508del variant. One study examined monotherapy with FDL169 versus 
placebo (Horsley 2017)(160). Three studies examined triple therapy, one phase one study 
with VX-659-tezacaftor-ivacaftor versus placebo, one phase 2 study with VX-659-tezacaftor-
ivacaftor versus placebo or dual combination control (Davies 2018 a & b)(152); and one 
phase 2 study of VX-445-tezacaftor-ivacaftor versus placebo or dual combination control 
(Keating 2018) (151). 
4.4.1.1 Monotherapy versus placebo or control 
The Horsley study found a statistically significant improvement at the 400 mg dose versus 
placebo in the absolute change in FEV1 % predicted, MD 4.68 % predicted (95% CI: 0.12 to, 
9.24). Though statistically significant, it is uncertain whether this improvement is clinically 
significant. No such significant changes in FEV1 were found at other dose levels. 
A statistically significant increase was observed in the change from baseline of sweat 
chloride for the 600 mg dose of FDL169 versus placebo, MD 8.84 mmol/L (95% CI 1.40 to 
16.28). No such significant changes in sweat chloride were observed at other tested doses.  
There are no significant concerns in safety at any dose when compared to placebo and one 
abstract stated that FDL169 will be studied in combination with FDL176, a potentiator 
(160). 
4.4.1.2 Double combination therapy versus placebo or control 
No new data for double combination therapies was added as of this update. Evidence 
shows that it can lead small improvements in measures such as pulmonary function, but 
the combination of lumacaftor-ivacaftor has been associated with significant adverse 
events such as transient increases in dyspnoea and raised blood pressure. Tezacaftor-
ivacaftor has not been associated with these adverse events. 
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4.4.1.3 Triple combination therapy versus placebo or control 
Both triple therapy combinations led to a statistically significant increase in QoL across 
multiple doses for people with CF who have one or two F508del gene variants. In two of the 
doses of VX-659 (240 mg and 400 mg) tested in people with the F508del/MF genotype, 
there was no significant improvement in QoL (151, 152). 
For triple combinations including VX-659, there was a significant improvement in both 
absolute and relative change in FEV1 from baseline compared to placebo for people with CF 
with one or two copies of F508del. For the F508del/MF participants in the 400 mg VX-659 
group the relative change from baseline was MD 23.9 (95% CI 14.52 to 33.18) and the 
absolute change for this group was MD 0.52 L (95% CI 0.34 to 0.70). For the 
F508del/F508del participants, the relative change in FEV1 from baseline was 16.0% (95% CI 
8.6 to 23.4) and the absolute change was MD 0.35 L (95% CI 0.19 to 0.51) (152).  
For the VX-445 combination, similar results were found: for the F508del/F508del 
participants in the 200mg dose group the relative change from baseline in FEV1 was MD 
17.8% (95% CI 6.7 to 28.9) and the absolute change from baseline was MD 0.46 L (95% CI 
0.26 to 0.66); and for the F508del/MF participants taking 200 mg. The relative change in 
FEV1 was MD 25.90% (95% CI 15.57 to 36.23) and the absolute change FEV1 was MD: 0.57 L 
(95% CI 0.36 to 0.78) (151). 
There was no statistically significant difference in the occurrence of adverse events for any 
combination compared to placebo across both genotype groups (study period of four 
weeks). There were no unexpected adverse events related to the study drug. 
A statistically significant decrease in sweat chloride from baseline was observed across all 
dose regimens of both the VX-659 and VX-445 combinations compared to placebo for 
people with one or two copies of the F508del variant, e.g. for F508del/F508del participants 
in the VX-659 400 mg group, MD -45.20 mmol/L (95% CI -52.18 to -38.22) and for the 
F508del/MF participants in this treatment group, MD -54.30 mmol/L (95% CI -65.28 to -
43.32). Similarly, for the F508del/F508del participants in the VX-445 200 mg group, MD -
40.40 mmol/L (95% CI -51.46 to -29.34) and for the F508del/MF participants in this group, 
MD -36.90 mmol/L (95% CI -46.43 to -27.37) (151, 152). 
When data were pooled for triple combination therapies in people with CF with 
F508del/MF genotypes, it was found that triple combination therapies generally led to a 
statistically significant improvement in the measures of efficacy included in this review. 
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Participants with the genotype F508del/F508del were not included in this pooling of data as 
their different genotypes made them too different to be able to include their response to 
the triple combination therapies as part of the same pooled analysis. As the trials only 
tested one dose in those with F508del/F508del genotypes, and also did not test VX-561, 
there were no multiple groups of these participants to be combined together as part of 
another pooled analysis for this genotype. These homozygous participants were already on 
tezacaftor-ivacaftor before this trial as they were receiving the standard of care. 
4.4.2 Overall completeness & applicability of evidence 
4.4.2.1 Monotherapy versus placebo or control 
The data available for the phase 1 FDL169 study (Horsley) were only provided in a poster 
and conference abstract (160). 
4.4.2.2 Dual combination therapy versus placebo or control 
No new trials of dual combination therapy were identified by this latest update. 
4.4.2.3 Triple combination therapy versus placebo or control 
The phase 2 trials of triple combination therapy enrolled people with CF homozygous for 
F508del (F508del/F508del) and also people with CF with one copy of F508del and one MF 
variant (F508del/MF). They did not include people under 18 years of age. Data on younger 
people with CF will be required. The duration of the intervention in each study was 4 
weeks, meaning that more long term data on efficacy and safety will also be required (151, 
152). 
The phase 2 studies tested the triple therapy combination of VX-659 or VX-445 plus 
tezacaftor 100 mg once daily plus VX-561, a deuterated form of ivacaftor that has a longer 
half-life in the body than the typical ivacaftor formulation. This means it is taken once daily 
at the same dose (150 mg), rather than the typical 150 mg twice per day with standard 
ivacaftor. This combination was only tested in a group of participants with the F508del/MF 
heterozygous genotype, it is only used in combination with the maximum tested doses of 
VX-659 and VX-445. The studies do not state why a combination of VX-561 is tested in 
these trials, or why it is only tested in people with F508del/MF genotypes, or why it is only 
tested in combination with the maximum doses of the above medications (151, 152). 
When efficacy data was pooled, triple combination therapies were shown to have 
statistically significant improvement in QoL, relative and absolute change in FEV1 and 
absolute change in sweat chloride from baseline (151, 152).  
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4.4.3 Quality of the evidence 
Several studies in this review incorporated complicated study designs with multiple drug 
doses and genotype combinations. This reflects stringent regulatory requirements and the 
demanding processes needed to have a trial approved, therefore trialists may find it 
beneficial to get as much information from the same trial as possible. It can also reflect the 
desire to move quickly, to try & test the next step in treatment. The example of this here is 
the inclusion of a group of participants in both of the included phase 3 triple combination 
trials being allocated to take VX-659/445-tezacaftor-VX-561 as part of the same trial (151, 
152). 
4.4.3.1 Monotherapy versus placebo 
The Horsley study of FDL169 was early phase, meaning there was limited outcome data and 
 risk of bias was hard to judge (Tables 1 & 2) (160). 
4.4.3.2 Triple combination therapy versus placebo or control 
The early phase triple therapy trials were complex because they evaluated a number of 
factors; different doses, different genotypes (F508del/F508del and F508del/MF) and 
different forms of ivacaftor. This resulted in 8 different comparator groups. 
For the phase 1 and 2 studies examining VX-659 and the phase 2 study of VX-445, we 
judged the quality of the evidence to be low to moderate. All domains of risk of bias were 
low, except for unclear risks of blinding of outcome assessment and selective reporting 
(Tables 3, 4 & 5). Some outcomes stated in the trial's methodology were not reported 
(safety measures). The GRADE assessment led to downgrading of evidence due to members 
of the review team judging there to be unclear methodological information on the blinding 
of outcome assessors and potential selective reporting. It was also downgraded due to the 
small number of participants and the studies being conducted over a short timescale 
leading to possible imprecision of results. A further downgrade was justified due to lack of 
applicability of results as there is no data for children with CF or people with more severe 
disease(152, 160)  (Summary of findings tables can be found in the appendices). 
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4.4.4 Potential biases in the review process 
A comprehensive literature search using the Cochrane Cystic Fibrosis and Genetic Disorder 
Review Group’s register of CF trials and ongoing trials was conducted. Journal conference 
abstracts were also searched. Once searching was complete, two authors (JM & IS) 
individually judged the eligibility of results using the pre-determined inclusion and 
exclusion criteria. Studies that were eligible for inclusion had their data extracted 
independently by the same two authors, using a data extraction form that had been made 
beforehand. They also independently assessed risk of bias for each included study. Where 
any disagreement arose, a third author provided arbitration. Analysis of the data was also 
performed by JM & IS authors, using the Cochrane Review Manager software (194). Data 
analysis was also checked by the review’s statistician. This adherence to Cochrane 
methodology aimed to minimise the risk of bias throughout the processes of the review. 
This systematic review used all available published data. Authors of the studies were 
contacted for unpublished information and data on individual participants, but as of yet, no 
further data has been supplied. 
4.4.5 Agreements and disagreements with other studies or reviews 
We are not aware of any already published reviews of triple combination therapy for 
people with CF with at least one class II variant. However, during the writing process of this 
systematic review, we were made aware of a review and meta-analysis examining dual-
combination therapy (195) (as the previous edition of this systematic review did). We 
therefore decided to read and appraise this review for comparison:  
The review, written by Wu et al. and published in December 2018 examined efficacy and 
safety of dual combination of CFTR correctors and potentiators (monotherapy was not 
assessed). It looked at people with CF with F508del/F508del. Two studies included in this 
Cochrane Review were not included in the Wu review, although they did meet the eligibility 
criteria (169, 170). Also, for another dual combination study, the previous version of our 
Cochrane review included data from its cohort 1, but not cohorts 2 and 3 due to concerns 
over pooling the control group (161); the Wu review includes these data. Furthermore, our 
review only included heterozygous participants from the Donaldson 2018 tezacaftor-
ivacaftor study, due to other participants being pooled which negated the effects of 
randomisation (100). The Wu review includes all pooled and unpooled participants 
(including those not homozygous for F508del). Consequently, the total number of 
participants and results are different to those found in this Cochrane Review. The Wu 
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review presents a meta-analysis of efficacy data for both lumacaftor-ivacaftor and 
tezacaftor-ivacaftor therapies; however, we considered the interventions to have different 
mechanisms of action and hence did not combine the data. Finally, Wu did not report the 
adverse event of hypertension found with lumacaftor-ivacaftor therapy which we reported. 
In our opinion, the conclusions of the Wu review are not supported by their meta-analysis 
and overstate efficacy measures. In addition, the authors claim to demonstrate a dose-
response effect, but there is no evidence of this from the data presented. Much of the 
interpretation within the Wu review seems to be based on observational and 
"experimental" studies not actually included in the review, rather than evidence from their 
meta-analysis. 
4.5 Conclusions for Cochrane systematic review 
4.5.1 Implications for practice 
Currently, there is no evidence to support monotherapy correctors for people with cystic 
fibrosis with either F508del/F508del or F508del/minimal function genotypes. 
There are no new data on dual combination therapies to influence the conclusions 
presented for dual combinations in the previous version of this systematic review (99). 
Early phase studies for triple therapy combinations demonstrated an acceptable safety 
profile and tolerability with significant improvements in respiratory function and quality of 
life compared to placebo or control over four weeks in people (F508del/F508del and 
F508del/MF) with mild to moderate lung disease. The magnitude of the reported 
improvements in efficacy measures suggest the potential of these agents to provide a 
significant intervention for people with CF (F508del/F508del), but phase 3 study data are 
required before these agents can be recommended for clinical practice. 
4.5.2 Implications for research 
Post-market surveillance should continue for all of the mentioned therapies. Tezacaftor-
ivacaftor (which forms components of the new triple therapy regimens) appears so far to 
not have resulted in the adverse events recorded with lumacaftor-ivacaftor, however data 
on its safety in children is required, as well as long-term monitoring. 
It should also not be automatically assumed that these therapies have the same efficacy for 
various different type II variants (e.g. G85E). The pathway from the endoplasmic reticulum 
to the cell surface membrane are complex, and different problems to those seen in F508del 
may affect the trafficking of other CFTR variants. It is unclear whether correctors will prove 
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effective for people with type II variants other than F508del and this should be 
investigated. However, the smaller numbers of people with CF with these variants will 
make conducting studies in this population a challenge.  
It is positive that both F508del/F508del and F508del/minimal function genotypes have 
been included in the latest triple therapy trials. Continuation of this inclusive approach in 
future trials should be encouraged. 
Also, with future studies, methodology should be clearly reported to reduce risk of bias; for 
example, the randomisation and blinding processes, as well as maintaining randomisation 
during data analysis to avoid loss of randomisation during pooling of some results. 
With previous concerns raised about adverse events in some of these therapies, reporting 
of safety and adverse events in novel treatments is paramount and should be conducted 
consistently and comprehensively. 
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5. A study of clinical outcome measures in trials for 
pre-school children with CF 
 
5.1 Introduction 
5.1.1 Background 
There is currently no agreed COS for pscwCF. Creation of a core outcome set will increase 
quality of trials in this age group, improve validity of meta-analyses and provide more 
meaningful information for all stakeholders involved in the care of pscwCF. 
 
Figure 10: Skill formation and the economics of investing in disadvantaged children. Heckman JJ. Science. 2006 
Jun 30;312(5782):1900-2 (196) 
It has been shown that early intervention leads to benefits of a greater magnitude in the 
future. Though not specific to children with CF (figure 10 above examines investments to 
benefit disadvantaged children), Heckman highlights the increased value of positive input 
early in a child’s life versus leaving the same measures until later in a person’s life. This 
same principle applies to pre-school children with CF and highlights just how important it is 
to ensure the best outcomes are measured during the pre-school years (196). An example 
specific to CF is shown in a retrospective observational study by Dijk et al., which compared 
outcomes in a group with CF detected through newborn screening, compared to a historical 
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control group who were not screened. The screened cohort (with earlier intervention) had 
slightly better growth and lung function, lower pseudomonas acquisition and better 
survival (see figure 11 below) (197). Small changes in the early years led to large differences 
in survival, a phenomenon similar to that of the Heckman curve which reaffirms the 
message that high quality benefits at an early stage will make large, lasting benefits in the 
future, which is what makes creation of a COS for pscwCF an important aim. The challenge 
of clinical trials in pscwCF is identifying meaningful outcomes and performing sufficiently 
powered studies to detect the small differences which will likely be important in early adult 
life. 
 
Figure 11: Kaplan-Meier survival plot of screened (dark line) versus non-screened (grey line) people with CF from 
Dijk et al. (197) 
Further beneficial applications of a COS include the fact that they allow us a standardised 
measure of the progress a child and their family is making by tracking the outcomes which 
we would know are the most important markers or measures of their wellbeing and 
happiness over time. A COS may also improve access to new therapies, as we could have a 
better knowledge of which outcomes matter most when evaluating medicines, improving 
rapid access to new therapies for pscwCF. Additionally a core outcome set can contribute 
towards comparative effectiveness research, where different investigations, interventions 
and their benefits and risks are compared (198). A COS allows us to consistently measure 
outcomes to determine which intervention provides the greatest benefit and least risk. 
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To produce a robust COS requires rigorous preliminary work and methodology. The first 
step of this is to review the current state of outcome reporting in this group. Monitoring for 
safety is typically similar throughout trials, with recording of adverse events during the trial 
and through post-market surveillance afterwards, with awareness of the possibility of 
‘unknown unknowns’. Efficacy related outcomes can differ considerably depending on the 
condition being included, the demographics of participants and the intervention being 
tested. 
5.1.2 The distinct challenge and need for a COS in pscwCF 
There is currently no core outcome set for pre-school children with CF. Fewer clinical trials 
are conducted in pscwCF when compared to those who are older. It is therefore imperative 
to improve the quality and consistency of trials. This would lead to a higher yield from 
research for all stakeholders and improve the outlook for pscwCF in the future. It is also not 
ethical to ignore this group when previously existing work on core outcomes does not 
adequately address their needs or challenges. 
 A core outcome set would help facilitate a higher quality trial that is more valuable to all 
stakeholders involved in the care of pre-school children with CF. 
A similar review published in 2016 searched for primary research (not just RCTs) in pscwCF. 
It examined three outcomes: 1) At what age have CF-related dysfunction and structural 
differences been shown in pscwCF? 2) At what age has progression of disease been 
demonstrated in pscwCF? 3) At what ages does early versus late intervention show 
improved outcomes in pscwCF? As part of its search strategy, it found that a low proportion 
of primary research in people with CF was conducted in preschool children. In this small 
proportion of research, a large number of measures relating to current disease state were 
reported (199). 
5.1.3 Aim 
Review and collate which outcome measures are reported in high quality RCTs including 0-5 
year old children with CF in their study population. To identify high quality trials, we 
interrogated the Cochrane library of reviews and trials.  
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5.2 Methods 
5.2.1 Outcomes to be measured: 
1. Frequency of what efficacy outcomes are measured by the systematic reviews, and 
their included trials. 
2. Quality of trials in this age group- risk of bias analysis for the included RCTs (not 
systematic reviews) 
3. Do the systematic reviews and trials examine exclusively pscwCF, or older children 
or adults as well? 
5.2.2 Eligibility criteria: 
For both Cochrane systematic reviews and RCTs:   
• Examine an intervention 
• Reported outcomes include those relating to efficacy of the intervention 
For Cochrane systematic reviews:  
• To include randomised controlled trials which included 0-5 year olds with CF as part 
of their recruited study groups 
For randomised controlled trials: 
• To be included in a Cochrane systematic review 
• To include a process of randomisation 
• To include a control group 
• Panel decision during information gathering: recruited study population to consist 
exclusively of 0-5 year olds. 
Another component of this work is a Cochrane systematic review, an example of high-
quality literature and comprehensive data searching. It was therefore decided that 
Cochrane reviews would provide an ideal source of trials as a sample to represent the state 
of outcome reporting in this age group. 
 
 
 
98 
 
5.2.3 Identifying eligible papers: 
The Cochrane Library of systematic reviews was searched using the term ‘cystic fibrosis’ on 
8th October 2018. 
Each Cochrane review in the search result was initially screened by title, then abstract, then 
full paper if necessary. Once this was completed, for each of the Cochrane reviews which 
were eligible so far, their ‘characteristics of included studies’ sections were examined to 
check for trials which included 0-5 year olds, and also that they were randomised, 
controlled trials. In the case that this information was not provided in the ‘characteristics of 
included trials’, the full versions of the trials in question were obtained and checked for this 
information. If there was uncertainty as to whether a given trial included participants aged 
0-5, it was excluded, meaning its respective Cochrane review may also be excluded, should 
it not include any other eligible trials. 
Once eligible Cochrane systematic reviews were identified, each of their included trials 
were again screened by title, abstract and full text where necessary, according to the above 
eligibility criteria. 
The panel excluded a number of the Cochrane reviews concerned with interventions that 
are not appropriate for 0-5 year olds with CF. 
A decision was also made as a panel to include randomised controlled trials which 
exclusively included 0-5 year olds as their study population. This was partly due to the 
finding of several trials including a very small number of participants, often just one 
participant in our eligible age group of 0-5 year olds, with the remainder being older 
children or adults. As a panel we felt this did not make for the best reflection of outcomes 
reported in pre-school children with cystic fibrosis. Although outcomes from these “wider” 
studies will be compared to this group of outcomes in future work. 
5.2.4 Data extraction 
For eligible reviews and trials, we attempted to retrieve a published protocol. This was 
possible for all but one Cochrane review, where the Cochrane cystic fibrosis & genetic 
disorders group was contacted, who recommended we use the methodology in the first 
version of the review itself, as the closest available approximation to the protocol. 
Protocols for included trials were searched for, and their respective authors contacted. Two 
authors replied. 
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5.2.5 Themes of outcomes 
Also at this stage, the panel grouped each of the eligible reviews and trials into one of the 
following predetermined themes, relating to different areas of treatment for CF: 
1. Managing CF airways disease 
-Antibiotics 
-Airway clearance/physio 
-Aerosolised therapies 
-Other 
2. Managing CF nutrition 
3. Managing CF liver disease 
4. Other 
Outcomes were extracted from protocols (where available), methodology, and results 
sections. This was with the intention in the future to assess both the outcomes which trials 
and reviews say they will examine and compare this with the outcomes they report in 
results.  
Outcomes were initially recorded as a list for each review and trial, with the frequency of 
which that each outcome was listed then being counted and recorded. The frequency 
recorded corresponds to the number of reviews/trials which state or report this outcome in 
their respective protocol, methods or results. A separate list was made and count was 
performed for first the Cochrane reviews, and then for the randomised controlled trials. 
Once outcomes were counted and recorded, they were also grouped into themes. It was 
found that the themes for the papers didn’t best transfer to individual outcomes, and so a 
more applicable set of themes were devised by the panel, which reflected different 
components of treating and monitoring someone with CF:  
1. Airway 
2. Extra thoracic disease 
3. Patient/parent reported outcomes 
4. Nutrition 
5. Microbiology 
6. Other 
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In addition to our own themes, we also classified the outcomes into the COMET initiative’s 
taxonomy (100): 
1. Death 
2. Physiological/clinical 
3. Life impact 
4. Resource use 
5. Adverse events 
We then counted the number of outcomes in both our themes, and COMET themes. 
Some of the outcomes stated fitted into two COMET themes, and hence were counted 
under both themes. 
5.2.6 Risk of bias 
All included trials also had their risk of bias evaluation checked. This was used as a marker 
of the quality of included trials. All included trials had a risk of bias evaluation already 
performed and available within their respective Cochrane reviews. If this was not the case 
however, we would have performed the same risk of bias evaluation as used in the 
Cochrane process (153). 
The rule for deciding overall risk of bias was: 
One or more category showed unclear risk of bias = overall unclear risk of bias 
One or more category showed high risk of bias = overall high risk of bias 
If all categories were low risk of bias = overall low risk of bias 
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5.3 Review of outcomes- results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 Cochrane systematic reviews and 10 randomised controlled trials went on to data 
extraction. 
 
 
 
195 Cochrane systematic 
reviews identified on initial 
searching. 
39 Cochrane systematic reviews 
identified as meeting eligibility 
criteria. 
164 Cochrane systematic 
reviews did not meet eligibility 
criteria and were therefore 
excluded. 
Publications relating to 10 
eligible randomised controlled 
trials (1 being a crossover study, 
the rest being parallel) were 
subsequently identified from the 
eligible Cochrane reviews. 
Decision made to only include 
randomised controlled trials 
which exclusively include 0-5 
year olds. 
31 Cochrane systematic reviews 
identified as relevant to pre-
schoolers. 
8 Cochrane systematic reviews 
excluded by panel decision for 
not being considered relevant to 
pre-school children with CF. 
Figure 12: PRISMA flowchart showing results of search and eligibility assessment 
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5.3.1 Frequency of what efficacy outcomes are measured by the systematic 
reviews, and their included trials. 
In the count of outcomes reported by the included Cochrane systematic reviews, 139 
different outcomes were reported in at least one of the protocol, methods or results 
sections of at least one of the included papers. 
5.3.1.1 Breakdown of findings from systematic reviews:  
Protocol stage: 
Protocols were available for 30/31 included Cochrane systematic reviews. For the one 
review whose protocol was not available, we first attempted to locate the protocol. After 
this was unsuccessful, and following advice from the Cochrane CF & Genetic Disorders 
Group, we elected to identify the outcomes stated in the methods section of the earliest 
draft version of this review, which is available on Archie, Cochrane’s review archive site, as 
this was the first piece written following the protocol and would most closely resemble its 
methodology.  
For COMET themes and the frequency of their included outcomes, it is important to 
remember that several outcomes have been classified under two different COMET themes, 
and have therefore been counted in both themes. 
 
 Protocol Methods Results 
 Number of 
different 
outcomes in 
each theme 
Total 
frequency 
that 
outcomes in 
this theme 
are reported 
Number of 
different 
outcomes in 
each theme 
Total 
frequency 
that 
outcomes in 
this theme 
are reported 
Number of 
different 
outcomes in 
each theme 
Total 
frequency 
that 
outcomes in 
this theme 
are reported 
CF Theme       
Airway 25 102 25 106 18 88 
Extra-thoracic disease 16 16 17 17 14 14 
Patient/parent reported 
outcomes 
5 28 5 31 3 26 
Nutrition 9 37 11 37 10 33 
Microbiology 18 71 17 85 17 73 
Other 21 103 23 120 20 121 
Total 94 357 98 396 82 355 
       
COMET theme       
Death 2 18 2 18 2 19 
Physiological/clinical 70 223 73 239 63 214 
Life impact 7 39 9 45 7 41 
Resource use 13 52 13 65 12 59 
Adverse events 12 35 14 40 11 37 
Total 104 367 111 407 95 370 
Table 7: Number of different outcomes reported under each CF-specific theme and COMET theme and the total 
frequency of outcomes reported under each theme for the protocol, methods and results stage of included 
systematic reviews. 
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5.3.1.2 Breakdown of findings from randomised controlled trials 
Protocol stage 
Despite efforts to contact the authors of every included trial, only 2/10 authors replied to 
provide the protocols for their respective trials. It was therefore decided that this provided 
an insufficient amount of data with which to add meaningful information to our analyses 
and conclusions. We therefore decided to focus on the methods and results sections of the 
included randomised controlled trials. Should we receive more protocols in the future, this 
may allow the protocols of these trials to be included in further analysis. 
 
Methods & results stages 
 Methods Results 
 Number of different 
outcomes in each 
theme 
Total frequency that 
outcomes in this 
theme are reported 
Number of different 
outcomes in each 
theme 
Total frequency that 
outcomes in this 
theme are reported 
CF Theme     
Airway 12 15 17 36 
Extra-thoracic disease 6 6 5 6 
Patient/parent reported 
outcomes 
2 2 3 4 
Nutrition 7 15 5 15 
Microbiology 13 23 16 26 
Other 20 36 19 40 
Total 60 97 65 127 
     
COMET theme     
Death 1 1 3 3 
Physiological/clinical 52 80 54 97 
Life impact 4 5 7 10 
Resource use 7 12 7 19 
Adverse events 2 6 2 6 
Total 66 104 73 135 
Table 8: Number of different outcomes reported under each CF-specific theme and COMET theme and the total 
frequency of outcomes reported under each theme for the methods and results stage of included randomised, 
controlled trials. 
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5.3.2 Quality of trials in this age group- risk of bias analysis for the included 
RCTs (not systematic reviews) 
 
Trial UK’ 91 
screening 
Wisconsin 
’98 
screening 
Button 
‘03 
Doumit 
‘12 
Stutman 
‘02 
Gibson 
‘03 
Wainwright 
‘11 
Rosenfeld 
‘12 
Cohen 
‘05 
Costantini 
‘01 
Adequate 
sequence 
generation? 
          
Allocation 
concealment? 
          
Blinding? All 
outcomes 
          
Incomplete 
outcome data 
addressed? 
All outcomes 
          
Free of 
selective 
reporting 
 Not in 
risk of 
bias table 
        
Free of other 
bias 
          
Overall risk of 
bias 
          
Table 9: Risk of bias assessments, including overall risk of bias, for all included RCTs. A larger version is available 
in the appendix. 
5.3.3 Do the systematic reviews and trials examine exclusively pscwCF, or 
older children or adults as well? 
As mentioned in the methods, a decision was made to only use randomised controlled trials 
which exclusively included participants in the 0-5 year old age group. This was due to many 
previously eligible trials containing just one or very few 0-5 year old which led to the panel 
deciding that to include trials exclusively examining the age group of interest would give a 
better representation of outcomes reported in pre-schoolers with CF. 
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5.4 Discussion of study of outcomes in pscwCF 
The low number of trials, the majority of which had high or uncertain risks of bias, 
combined with the large variety of outcomes and their themes highlight the difficulty in 
conducting research in young children and in identifying what are best outcomes to 
consider as part of this research. A disproportionately high number of outcomes were 
short-term, surrogate biomarkers which gave a snapshot of disease state/condition of the 
person at that time. A considerably smaller proportion of outcomes reflected the longer 
term, lived experience for children and their families. Some established outcomes such as 
FEV1 and similar are generally agreed to not provide valuable information for pre-school 
children. It is difficult for a child of pre-school age to perform tests such as spirometry in 
such a way that they give reliable information. Regardless of this consideration, such 
outcomes were measured and reported by included trials more frequently than those 
longer-term patient-centred outcomes. For example, FEV1 was reported in the results of 
5/10 trials, whereas quality of life was reported in the results of 1/10 trials. Other short-
term measures were regularly recorded, for example FEF 25-75 (forced expiratory flow at 
25-75% of the pulmonary volume) was reported in the results of 6/10 trials. Other, more 
recent methods of representing current disease state, such as lung clearance index (LCI) 
were stated by 6 of the included systematic reviews, but not reported by any included trial. 
This could be due to included trials testing interventions not related to airways disease, or 
the trials being performed and published before these more recent investigations became 
as accepted as they currently are as we did not set a time limit as part of our eligibility 
criteria. It is not necessarily bad that numerous surrogate outcomes are measured, as many 
may provide useful information. However it is also important to highlight that other, 
pragmatic outcomes can also give useful information and may be under-represented by 
trials.  
A total of 65 different outcomes were reported in the results of the included RCTs. 
Considering the example of airway measures (one of the CF themes proposed by the 
research team), 17 different outcomes were reported. 16 different outcomes related to 
microbiology were reported. This large number of outcomes can increase variability 
between trials. This makes meta-analysis more difficult. 
This work can serve to highlight the need for more trials to be conducted in this age group, 
as well as the importance that these trials must be of as high a quality as possible. Creation 
of a core outcome set will provide guidance on those considering performing research with 
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this group. It will also lead to improvements in the quality of this research and the value of 
its conclusions which can be drawn upon by many, if not all stakeholder groups. A core 
outcome set can also encourage the use of both novel investigations and tried & tested 
investigations of value, whilst discouraging the measurement of less useful information. 
The standardisation of outcome reporting could reduce heterogeneity and allow for 
improved incorporation into systematic reviews and meta-analyses. 
Limitations of this work: This review used the Cochrane library of systematic reviews as its 
source to identify firstly relevant Cochrane systematic reviews and subsequently 
randomised controlled trials. A possible limitation of this work is that non-Cochrane 
systematic reviews which otherwise meet our eligibility criteria may therefore not have 
been identified by our search strategy. This may in turn mean that some RCTs which may 
have provided useful information may also not have been included. Additionally, it should 
be acknowledged that forms of research other than RCTs, for example cohort studies, may 
have also provided valuable information on outcomes for pre-school children with CF. 
Although this work is not itself a Cochrane review, it uses them as a source of information 
and thus reflects their methodology. Cochrane reviews often specify the design of included 
studies must be RCTs, meaning they exclude other study designs, again such as cohort 
studies. Though this means that Cochrane reviews and therefore this study identify what is 
typically considered the gold standard of primary research, they may miss studies which 
may still be conducted to a high standard and provide useful data. As Cochrane reviews are 
expected to have a comprehensive search strategy which identifies all studies meeting its 
eligibility criteria, there should not be an issue of eligible studies not being identified by 
Cochrane systematic review search strategies. 
We also found that many of the included Cochrane reviews stated that if there was no data 
found for an outcome which they had pre-specified to report on, they would not report this 
outcome. Some reviews still reported these outcomes and stated that no data were 
available. Other reviews however did not specify that no data were available and instead 
simply did not include/report upon this outcome. This meant it was sometimes not possible 
for us to distinguish between whether there was simply no data for these outcomes, or 
whether any selective reporting bias was present within the included Cochrane systematic 
reviews. 
Additionally, we evaluated quality by means of risk of bias. Other tools relating to quality of 
evidence, such as GRADE could have been used, this additional quality appraisal could be 
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performed for future publication of this work, to further increase the robustness of its 
findings and conclusions.  
The next steps toward creating a core outcome set for this group will involve making 
contact with many stakeholder groups to seek their involvement and contribution towards 
a Delphi survey (as described above), followed by a group consensus study to identify that 
optimum set of outcomes. Once this is done however, the process is not complete. Core 
outcome sets can be continually reviewed and improved over time as new investigative 
tests emerge, priorities of preschool children with CF and their families change or provision 
of services alters. 
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6. Discussion 
6.1 Summary and implications 
There is no evidence to support the use of corrector monotherapy in people with CF with at 
least one copy of an F508del variant. We await the results of trials testing novel correctors 
in monotherapy e.g. GLPG2222 (189, 190). 
No new trials testing dual combination therapies were identified by this review. 
Tezacaftor/ivacaftor remains the dual combination standard of care for those with CF who 
have two copies of F508del as it shows similar efficacy to lumacaftor/ivacaftor in 
statistically significant improvements in respiratory function, but without the significant 
adverse events and less desirable pharmacological properties of lumacaftor. No new data 
was provided for dual combination therapies for people with CF with one copy of F508del 
and another variant, such as a minimal or residual function variant. In the triple therapy 
trials, tezacaftor-ivacaftor was used as the standard of care for the control group in 
participants with 2 copies of F508del. For the triple therapy trials examining impact on 
F508del/minimal function patients, a triple placebo was given. 
This is the first systematic review of triple combination CFTR modulator therapy. Triple 
therapy (in a number of different combinations) resulted in statistically significant 
improvements in two of the review’s three primary outcomes of quality of life and 
pulmonary function in people with CF aged over 12 years with either one or two F508del 
variants. The third outcome, survival, was not analysed by the included triple combination 
trials. The improvements seen were similar in magnitude to those seen in trials testing 
ivacaftor in people with CF with type III variants (151, 152). 
These results suggest that a significant pharmacological therapy may be available to people 
with CF with at least one copy of an F508del variant. Triple combination therapy is still in 
trial stages; however it may soon be available outside of trials. Currently the most recently 
approved regimen for people with CF with 2 copies of F508del variants is dual combination 
tezacaftor-ivacaftor, however this is only currently available in 4 countries, Denmark, 
Germany, Iceland and The Republic of Ireland. Lumacaftor-ivacaftor is available in 10 
countries, including the UK (200), where it is used through a managed access scheme for 
patients with poor condition. The manufacturer of these drugs produced a press release on 
31st May 2019 stating that they had chosen to submit VX-445 (named elexacaftor) in triple 
combination with tezacaftor-ivacaftor for global regulatory approval (201). They have not 
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chosen to do the same with VX-659. This decision is based on phase 3 trials that have not 
been published and were not available for this review. The summary data in the press 
release suggest a similar magnitude of effect to that outlined in this review from the phase 
2 trials. 
Triple therapies may form the next major step in treating people with CF with one or two 
copies of F508del. These combinations must be carefully evaluated for safety and efficacy, 
especially in children and young people, including in pscwCF. In this age group, the most 
appropriate outcome measures must still be determined. 
The phase 2 trials included an arm that examined VX-561 (deuterated ivacaftor) at a once 
daily dose instead of ivacaftor. Our forest plot suggests this regimen resulted in as good a 
response, if not a greater magnitude of improvement than the triple combination with 
normal ivacaftor (figures 6 to 9). This drug was likely tested as part of the same trials in 
order to allow it to pass through approval and trial processes quicker (202). Included trials 
only tested VX-561 in participants with F508del/MF genotypes. It should also be tested in 
homozygous people and in children. Despite the positive results and the once per day 
dosing, VX-561 has not yet been submitted for regulatory approval. 
The cost of these therapies is currently high, and this may limit access for many people with 
CF who could benefit from them. The health technology assessment undertaken in the UK 
for lumacaftor/ivacaftor did not result in approval. If for example, triple therapy was 
approved for use in the UK, and if we assume it costs similar to that of ivacaftor quoted by 
the BNF as £500 per day, then according to the CF trust’s latest registry report, 8834 people 
with CF may be eligible for these medicines in the UK (4852 F508del/F508del, 3982 
F508del/Other variant) (203). If all of these people start the medication, then the yearly 
cost to the NHS would be £1,612,205,000 (£1.6 billion). In 2017/18, the NHS’ total budget 
for the year was £124.7 billion (204).  
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6.2 Trials & outcome measures in trials of pscwCF 
For most CF studies, absolute change in FEV1 is the primary outcome measure. Measures of 
pulmonary function are challenging in pscwCF. Recent studies in pscwCF have used multiple 
breath washout technique to measure lung clearance index (LCI). Following use as a 
secondary outcome measure in the ISIS study and promising data (145, 205), the SHIP 
(Inhaled hypertonic saline in pre-school children with CF) RCT published June 2019 
employed LCI2.5 as its primary outcome as the investigators felt it can give more valuable 
information than previous conventional pulmonary function tests in this age group. LCI is a 
time-consuming investigation that still requires cooperation from the child and skilled 
investigators. The SHIP study demonstrated a significant reduction in LCI in children 
receiving twice daily hypertonic saline compared to children receiving normal saline. 
Commentators considered this to be an intervention that should be considered for all 
pscwCF, but this needs to be balanced against the addition in treatment burden (72, 73).  
The James Lind Alliance, an initiative which consults stakeholders to determine the 
priorities for research in a specific condition which they want addressed, these are called 
priority setting partnerships (PSPs). The PSP for people with CF found treatment burden 
was considered the most important priority to address (the full PSP top 10 priorities list can 
be found in the appendix) (206). People with CF and stakeholders may find it very valuable 
if trials reported upon endpoints examining the impact on treatment burden. The new 
triple combination CFTR modulating therapies and future therapies may play an important 
role in reducing treatment burden; but as of now trials of these new combination therapies 
are not considering this outcome.  A retrospective analysis of people with CF with a G551D 
variant taking ivacaftor monotherapy found that over two years of ivacaftor treatment 
there was a statistically significant decrease in the prescription of azithromycin, dornase 
alfa, inhaled bronchodilators, inhaled corticosteroids and oral supplements. The decreases 
seen in hypertonic saline, inhaled antibiotics and pancreatic enzymes were not statistically 
significant (207). It is important to note that though statistically significant, this does not 
tell us whether the results were clinically significant and whether the participants felt their 
treatment burden had improved. The age range of this analysis was from age 6 to 51, 
median age 17; therefore these results may not directly transfer to pscwCF but are still 
valuable.  
Our study of outcome reporting found that trials in pscwCF reported a wide variety of 
outcomes and these outcomes were predominantly surrogate markers giving a short-term 
measure of disease activity. There was a lack of validated measures of the direct impact of 
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CF on a child and their family, as well as markers of longer-term wellbeing. This agrees with 
the similar review mentioned in section 5.1.2 (199). There are lots of modalities of trying to 
detect pathology, but it is difficult to know which measures are the best in this age group, 
as pscwCF are generally well, may not be cooperative and as a result it is difficult to 
perform investigations to give a valid result. Although we may be able to detect presence 
of, or change in disease state, we may not know if this translates to a meaningful difference 
in the wellbeing of the child with CF and their families. This similar review also found very 
few pragmatic outcomes directly relating to the current and longer term wellbeing of the 
child & family (199). As this other review looked at various forms of primary research, not 
just RCTs, this can show that the lack of these pragmatic outcomes is not exclusive to RCTs 
and is an issue throughout research in pscwCF.  
The design of trials can have an important impact on the value of results, for example in the 
KIWI study (and its extension, KLIMB), which were open label single arm studies of ivacaftor 
in pscwCF aged 2-5 years. A rise in liver function tests was observed in 30% of participants 
by the end of KLIMB (120, 208). The lack of a placebo group means it is difficult to reliably 
say whether this was an adverse effect of the test intervention or reflective of the normal 
natural history for pscwCF. 
Our Cochrane review included outcomes such as: number of admissions and days spent in 
hospital, measures of attendance at work/school. These are important outcomes which 
play a role in reflecting the ability to live as ‘normal’ a life as possible. None of the new 
trials in this review include such outcomes, but they are phase 2, short term studies. Since 
completion of this systematic review, both VX-659-tez-iva and VX-445-tez-iva are awaiting 
release of phase 3 study results and an open label extension has been announced for both 
VX-659-tez-iva (ECLIPSE) and VX-445-tez-iva (AURORA) (209). The rationale for these 
studies states that the studies will include participants age 12 and older and will not include 
younger children (209). The primary outcome will be absolute change in percent predicted 
FEV1 and they will include CFQ-R respiratory domain and pulmonary exacerbations (both 
number of and time to) as part of their secondary outcome analyses. Outcomes such as 
school attendance, time spent in hospital etc. are not recorded in the protocol. They will 
also include safety over a longer time period (24 week study period followed by 96 week 
open label extension) (209). Earlier phase trials have not yet been initiated to assess safety 
in younger & preschool children. They could therefore not be included in this longer-term 
study despite what we already know that younger children have the potential to get the 
greatest magnitude of benefits over the long term from such interventions. Once safety is 
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established in older participants, more focus should be placed earlier on the assessment of 
safety of these therapies in young children; followed by if they improve & extend the lives 
of these children and their families, and by what magnitude. A COS would improve the 
likelihood of this occurring. 
6.3 Future work 
The Cochrane systematic review will again need updating in the near future to keep pace 
with the new corrector therapies being tested and results from the phase 3 triple therapy 
trials, once published. Future versions of this review can also include an assessment of cost-
effectiveness of therapies. 
 The work reviewing outcomes in pscwCF will be produced as a paper and submitted for 
publication. Included in this report will be an analysis of selective reporting bias in these 
trials; essentially recording all outcomes measured as stated by published protocols and 
comparing those to the outcomes that are actually reported once the trial is completed. 
Formation of a core outcome set will require stakeholder engagement through Delphi 
consensus study to generate agreement on an initial core outcome set. 
 
7. Conclusion 
Corrector medications, when used in combination therapy with a potentiator, has the 
potential to make substantial improvements to the wellbeing of people with CF with at 
least one copy of a F508del CFTR variant. The latest combinations of therapy require testing 
in children, including pscwCF. A core outcome set would provide more consistent and 
meaningful outcomes for all stakeholders involved in the care of pscwCF. 
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Figure 13: Example of MHRA yellow card for reporting adverse events in medications, as included in the British 
National Formulary book. 
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Example data extraction sheet used for this update of Cochrane review 
Continuous data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
Dichotomous data 
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Ongoing studies for Cochrane systematic review 2019 
Monotherapy 
Two studies are testing GLPG2222 (Bell 2017; Van der Ent 2018). One phase 2, placebo-
controlled multicentre trial in Australia and Europe known as ALBATROSS is testing 150 mg 
daily or 300 mg daily of GLPG2222 for four weeks in 37 adults with CF with an 
F508del/Class III variant genotype who are already on stable ivacaftor regimens (188, 189). 
The outcomes they state will be reported include adverse events, pharmacokinetic data, 
concentration of sweat chloride, pulmonary function and quality of life. The second study, 
known as FLAMINGO and is also a multicentre phase 2 study taking place in North America 
and Europe (190, 191). This study is testing a range of doses of 50 mg to 400 mg four times 
per day of GLPG2222 for four weeks in adults with CF homozygous for F508del and a 
baseline FEV1 of 40% predicted or more who have not taken other CFTR correctors in the 
previous four weeks. Stated outcomes include adverse events, sweat chloride 
concentration, pulmonary function, quality of life and pharmacokinetic data. 
Two trials are studying PTI-428 (a class of CFTR modulator called an amplifier, which 
augments the actions of other CFTR modulators) (NCT02718495; NCT03258424). The first 
plans on recruiting 56 adults with CF (they do not specify class of variant) at 29 locations in 
Europe and North America (NCT02718495). The trial lasts 28 days of ascending doses (not 
stated) versus placebo. Stated outcomes include adverse events, pulmonary function, 
pharmacokinetics, sweat chloride concentration, weight and quality of life (NCT02718495). 
The second trial is a Phase I placebo-controlled RCT at two locations in the UK 
(NCT03258424). It is planning to recruit 16 adults with CF already taking stable ivacaftor for 
14 days of treatment with adding PTI-428, of which the dose levels are not stated. Outcome 
stated include adverse events, pharmacokinetics, sweat chloride concentration, pulmonary 
function and weight (NCT03258424). 
One phase 1 trials is studying PTI-801 both in monotherapy and in combination with PTI-
428 versus placebo in adults with CF (homozygous for F508del in three cohorts and 
heterozygous F508del in one cohort) with a baseline FEV1 of 40% to -90% and with a 
background therapy of lumacaftor-ivacaftor (193). It is a UK-based multi-centre study 
planning to enrol 32 participants, with treatment lasting 14 days with a follow-up visit at 
day 21. There are four arms, two 14-day arms comparing different doses of a combination 
of PTI-808 and PTI-801 against placebo, one 14 day arm comparing a triple combination of 
PTI-808, PTI-801 and PTI-428 versus placebo and one arm comparing PTI-808, PTI-801 and 
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PTI-428 to placebo for seven days followed by PTI-808 and PTI-801 versus placebo for a 
further seven days (with no washout period). Stated outcomes include adverse events, 
pharmacokinetics, pulmonary function, sweat chloride concentration, nutritional measures 
and quality of life. 
One multicentre RCT is comparing 200 mg or 400 mg of a corrector known as (R)-
roscovitine versus placebo in 36 adults with CF with either one or two copies of the F508del 
variant for three months (192). The primary outcome is safety with other outcomes 
including pharmacokinetics, quality of life, pulmonary function, body mass index, sweat 
chloride and nasal potential difference. 
One week long trial is comparing glycerol phenylbutyrate (GPBA) as an oral liquid in a low-
dose arm and in a high-dose arm against matched placebo in adults with CF, homozygous 
for F508del (NCT02323100). Stated outcomes include the adverse events, change in nasal 
potential difference, and sweat chloride concentration. 
 
Dual combination therapy 
Four ongoing trials are studying the safety and efficacy of tezacaftor-ivacaftor in people 
with CF; three trials are in people homozygous for F508del, one trial is phase 2 and multi-
centre (NCT02070744), One is particularly studying chest imaging endpoints 
(NCT02730208) and one study is a multicentre parallel phase 3b RCT examining the safety, 
tolerability and efficacy of tezacaftor/ivacaftor in participants with CF aged 12 years plus 
who have previously taken lumacaftor/ivacaftor (NCT03150719).  Another study is in 
heterozygous people with one copy of the F508del variant and one variant that is 
responsive to ivacaftor (NCT02412111). Another study is a parallel phase 3b parallel, multi-
centre RCT in people homozygous for F508del who have previously taken lumacaftor-
ivacaftor but discontinued due to an adverse event, with the aim of evaluating the safety 
and efficacy of tez/iva (NCT03150719). 
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Triple combination therapy 
Three placebo-controlled trials are evaluating triple combination therapies, one is studying 
VX-152 in triple combination with tezacaftor/ivacaftor (NCT02951195), One is a first-in-
human study of VX-445 conducted in people with CF who have either a F508del/MF 
genotype or A F508del/F508del genotype, as well as healthy participants without CF 
(NCT03227471). 
A Phase 2 placebo-controlled study is assessing the efficacy of cavosonstat when added to 
pre-existing lumacaftor-ivacaftor therapy in adults with CF who are homozygous for the 
F508del-CFTR mutation (NCT02589236). 
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Risk of bias assessment tables for all remaining included studies in Cochrane 
systematic review 2019 
Boyle 2014 
 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk An independent party used a computer to 
create a random sequence. 
Allocation concealment 
(selection bias) 
Low risk An interactive voice response system was 
used by pharmacists to dispense the 
medication. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk An independent pharmacist who was not 
masked prepared the doses of drug. The drug 
was then dispensed at each site by 
pharmacists who were masked to allocation. 
Placebo was matched in terms of number of 
tablets, their size, colour, packaging and 
coating. 
Blinding of outcome 
assessment (detection bias) 
Low risk Study team at each site and sponsor of study 
were masked to both treatment assignment 
and sweat chloride concentration. 
Incomplete outcome data 
(attrition bias) 
Unclear 
risk 
Data on a particular outcome for a 
participant was not included if it was 
insufficient. The example given is not 
including a participant's sweat chloride conc. 
data if an insufficient volume of sweat 
chloride was collected. It is unclear how 
excluding these data affects the balance of 
baseline characteristics between different 
participant groups.  
Selective reporting 
(reporting bias) 
Low risk No selective reporting of outcomes was 
found following comparison of this trial’s 
outcomes stated on clinicaltrials.gov 
(protocol not available) to outcomes 
reported in results. 
Other bias Low risk Baseline characteristics were similar between 
groups. 
Table 10: Risk of bias assessment table for Boyle 2014 (161). 
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Clancy 2012 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Unclear 
risk 
Method of randomisation not stated. 
Allocation concealment 
(selection bias) 
Unclear 
risk 
Method of allocation concealment not 
stated. 
Blinding of participants and 
personnel (performance 
bias) 
Unclear 
risk 
Not enough information was given regarding 
how blinding of participants and study team 
was maintained. 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk 
Not enough information was given regarding 
how blinding of outcome assessors was 
maintained. 
Incomplete outcome data 
(attrition bias) 
High risk Total number of participants that was stated 
in adverse events table (n=45) is less than 
total number who were randomised (n=89).  
 
Figure 1B concerns change from baseline of 
sweat chloride, it states 63 participants were 
analysed. This is less than the total number 
of participants randomised to the 
intervention (n=72). 
 
There is a table of results for CFQ-R scores 
where 1 participant is missing from each 
treatment group. 
Selective reporting 
(reporting bias) 
High risk FEF25-75%  and FVC were stated as outcomes 
but were not reported in results. 
Other bias Low risk Baseline characteristics were generally well 
matched except for those in the 25 mg and 
placebo groups with less severe lung disease. 
Table 11: Risk of bias assessment table for Clancy 2012 (162). 
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Donaldson 2014 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Unclear 
risk 
Method of randomisation not stated. 
Allocation concealment 
(selection bias) 
Unclear 
risk 
Method of allocation concealment not 
stated. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk Participants, investigators, outcome 
assessors and care providers were all masked 
to intervention. Matched placebo was saline 
given at same volume as the intervention 
drug. 
Blinding of outcome 
assessment (detection bias) 
Low risk Participants, investigators, outcome 
assessors and care providers were all masked 
to intervention. Matched placebo was saline 
given at same volume as the intervention 
drug. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation were accounted for. All 
completed follow up at seven days. 
Selective reporting 
(reporting bias) 
Unclear 
risk 
A full text of this trial was not available. 
Results are limited to those available on 
clinicaltrials.gov and do not have 
accompanying statistical analysis. It is 
unknown if any relevant information has 
been omitted. 
Other bias Low risk Small numbers in groups but baselined 
characteristics appear balanced. 
Table 12: Risk of bias assessment table for Donaldson 2014 (163).  
 
 
 
 
 
 
 
 
 
 
 
 
 
141 
 
Donaldson 2017 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Unclear 
risk 
Method of randomisation not stated. 
Allocation concealment 
(selection bias) 
Unclear 
risk 
Method of allocation concealment not 
stated. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk More information would be useful, however 
judged as likely low risk due to being a 
double blind, placebo-controlled study. 
Blinding of outcome 
assessment (detection bias) 
Low risk More information would be useful, however 
judged as likely low risk due to being a 
double blind, placebo-controlled study. 
Incomplete outcome data 
(attrition bias) 
Unclear 
risk 
2 participants have not been accounted for 
as part of analysis; however it is judged 
unlikely to have affected result. 
Selective reporting 
(reporting bias) 
Low risk All outcomes have been reported, but at 
other time points which have not been 
reported such as day 7 & 14. 
Other bias Unclear 
risk 
Gender imbalance- approx. two thirds of 
participants were female, but in the 200 mg 
twice daily group, there was a larger 
proportion of males. It is not known if these 
imbalances may have affected results. 
Table 13: Risk of bias assessment table for Donaldson 2017 (164) 
 
Donaldson 2018 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Unclear 
risk 
Method of randomisation not stated. 
Allocation concealment 
(selection bias) 
Unclear 
risk 
Method of allocation concealment not 
stated. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk Double blind randomised controlled trial. 
Uses a matched placebo. 
Blinding of outcome 
assessment (detection bias) 
Low risk Double blind randomised controlled trial. 
Uses a matched placebo. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation were accounted for in 
analysis. 
Selective reporting 
(reporting bias) 
Low risk All outcomes stated are reported 
Other bias Unclear 
risk 
Small numbers of participants across groups 
has led to imbalance of baseline 
characteristics- unclear if this has affected 
results. 
Table 14: Risk of bias assessment table for Donaldson 2018 (100) 
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McCarty 2002 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Unclear 
risk 
Method of randomisation not stated. 
Allocation concealment 
(selection bias) 
Unclear 
risk 
Method of allocation concealment not 
stated. 
Blinding of participants and 
personnel (performance 
bias) 
Unclear 
risk 
Not enough information was given on how 
participant or study team were blinded and 
how this blinding was maintained. 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk 
Not enough information was given on how 
outcome assessors were blinded and how 
this was maintained. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation were accounted for.  
Selective reporting 
(reporting bias) 
Low risk Outcomes reported in results were the same 
as those stated in the methods. The protocol 
was not available. 
Other bias Unclear 
risk 
Not known if baseline characteristics were 
balanced across groups. 
Table 15: Risk of bias assessment table for McCarty 2002 (165) 
PROGRESS 2017 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk As this was an open label continuation of 
previous trials, only the placebo groups were 
randomised. An interactive web response 
system was used for the randomisation 
process. Randomisation stratified according 
to demographics. 
Allocation concealment 
(selection bias) 
Low risk Only placebo groups were randomised by 
used of an interactive web response system. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk Both participants and study staff were 
blinded to treatment. 
Medications were matched in both 
appearance and packaging. 
Blinding of outcome 
assessment (detection bias) 
Low risk Both participants and outcome assessors 
were blinded to allocation. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation were accounted for. 
Selective reporting 
(reporting bias) 
Low risk All outcomes stated were then reported. 
Other bias Low risk Baseline characteristics were balanced across 
groups. 
Table 16: Risk of bias assessment table for PROGRESS 2017 (171) 
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Ratjen 2017 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Interactive web response system used to 
randomise participants, who were stratified 
by weight and percent predicted FEV1 
Allocation concealment 
(selection bias) 
Low risk Randomisation from interactive web 
response system. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk Placebo tablets were matched to test 
intervention tablets. 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk 
Does not say whether outcome assessors 
were blinded. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation were accounted for. 
Selective reporting 
(reporting bias) 
High risk Multiple outcomes were stated in methods 
but not reported in results. 
Other bias Unclear 
risk 
Similar baseline characteristics in both 
groups. 
Table 17: Risk of bias assessment table for Ratjen 2017 (168) 
 
 
Rubenstein 1998 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Unclear 
risk 
States that randomisation & blinding were 
performed by an independent party but does 
not state how. 
Allocation concealment 
(selection bias) 
Unclear 
risk 
States randomisation & blinding were 
performed by an independent party but does 
not state how. 
Blinding of participants and 
personnel (performance 
bias) 
Unclear 
risk 
Study describes itself as double blind. It 
states that randomisation & blinding were 
performed by an independent party but does 
not state how. 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk 
Study describes itself as double blind. It 
states that randomisation & blinding were 
performed by an independent party but does 
not state how. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation were accounted for. 
Selective reporting 
(reporting bias) 
Low risk Outcomes stated in methods were all 
reported in results. Protocol was not 
available. 
Other bias Low risk Baseline characteristics were balanced. 
Table 18: Risk of bias assessment table for Rubenstein 1998 (166) 
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Taylor-Cousar 2017 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Independent statistician made the 
randomisation code which was then used in 
an interactive web response system.  
Allocation concealment 
(selection bias) 
Low risk Interactive web response system was used. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk Participants and study team were blinded. A 
matched placebo was used. 
Blinding of outcome 
assessment (detection bias) 
Low risk Participants and study team were blinded. A 
matched placebo was used. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation were accounted for. Despite a 
small number of them being excluded, they 
are still accounted for and it is unlikely to 
have introduced bias. 
Selective reporting 
(reporting bias) 
High risk Multiple outcomes were stated in protocol 
but not reported in results. 
Other bias Low risk Final paper produced with help of medical 
writers, paid for by the sponsor, it is not 
thought that this introduced bias. 
Table 19: Risk of bias assessment table for Taylor-Cousar 2017 (169) 
 
 
 
TRAFFIC 2015 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Randomisation by use of web response 
system. Stratified by demographics. 
Allocation concealment 
(selection bias) 
Low risk Randomisation by use of web response 
system.  
Blinding of participants and 
personnel (performance 
bias) 
Low risk Participants and study staff blinded 
throughout. Placebo was matched to test 
drug by appearance and packaging. 
Blinding of outcome 
assessment (detection bias) 
Low risk Participants and study staff blinded 
throughout. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation have been accounted for. 
Selective reporting 
(reporting bias) 
High risk Several outcomes stated on clinicaltrials.gov 
were not reported in the paper. 
Other bias Low risk High adherence and compliance rates 
throughout trial. 
Table 20: Risk of bias assessment table for TRAFFIC 2015 (170) 
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TRANSPORT 2015 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Randomisation by use of interactive web 
response system. Stratified by demographics. 
Allocation concealment 
(selection bias) 
Low risk Randomisation by use of web response 
system. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk Participants and study staff blinded 
throughout. Placebo was matched to the test 
drug by appearance and packaging. 
Blinding of outcome 
assessment (detection bias) 
Low risk Participants and study staff blinded 
throughout. 
Incomplete outcome data 
(attrition bias) 
Low risk All participants who underwent 
randomisation were accounted for. 
Selective reporting 
(reporting bias) 
High risk Outcomes stated on clinicaltrials.gov were 
not reported in the paper. 
Other bias Low risk High adherence and compliance rates 
throughout trial. 
Table 21: Risk of bias assessment table for TRANSPORT 2015: (170) 
 
Zeitlin 2002 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Unclear 
risk 
Describes itself as randomised but does not 
describe the methodology behind this. 
Allocation concealment 
(selection bias) 
Unclear 
risk 
Does not state method for allocation 
concealment. 
Blinding of participants and 
personnel (performance 
bias) 
High risk Study team were aware of allocation, also 
likely that participants could become aware 
of allocation. 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk 
Not enough information given to describe 
how blinding of outcome assessors was 
maintained. 
Incomplete outcome data 
(attrition bias) 
Unclear 
risk 
All participants completed study, but authors 
do not state if all participants were included 
in analysis. 
Selective reporting 
(reporting bias) 
High risk Multiple outcomes stated in methods were 
not reported in results. 
Other bias Low risk Baseline characteristics were balanced. 
Table 22: Risk of bias assessment table for Zeitlin 2002 
 
Summary of findings tables for triple therapy combinations in Cochrane 
systematic review 2019. 
VX-659-tezacaftor-ivacaftor 
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Outcomes Illustrative comparative risks 
(95% CI) 
Relative 
effect 
(95% CI) 
No of 
Participa
nts 
(studies) 
Quality 
of the 
evidenc
e 
(GRADE) 
Comments 
Assumed 
risk 
Corresponding 
risk 
Triple 
placebo or 
placebo-
tezacaftor
-ivacaftor 
VX-659 plus 
tezacaftor plus 
ivacaftor or VX-
561 
Survival 
 
Follow-up: 2 
to 4 weeks 
No deaths 
reported 
No deaths 
reported 
NA 129  
(2 
studies) 
Low 
(1,2) 
 
Quality of 
life: total 
score 
Follow-up: 
NA 
Outcome not reported NA  
Quality of 
life: CFQ-R 
respiratory 
domain: 
absolute 
change from 
baseline 
 
Follow-up: 
up to 4 
weeks 
See 
comment 
Significant 
improvement 
seen in: 
F508del/MF 80 
mg group, MD 
10.00 (95% CI 
0.29 to 19.71); 
F508del/F508del 
group (400mg), 
MD 18.10 (95% 
CI 10.85 to 
25.35); and VX-
561 group, MD: 
20.3 (95% CI 7.1 
to 33.6). 
 
No such 
significant 
differences were 
seen in the 
other dose 
groups 
NA 117  
(1 study) 
Low 
(1,3) 
Higher 
score 
indicates a 
better 
outcome. 
Data were 
analysed 
via a 
MMRM. 
Results 
provided 
by this 
model can 
be 
interpreted 
as 
treatment 
effect 
averaged 
from week 
2 and week 
4. 
FEV1 (% 
predicted): 
relative 
change from 
baseline 
 
Follow-up: 
up to 4 
weeks 
See 
comment 
Statistically 
significant 
improvements 
seen in FEV1 % 
predicted 
relative change 
from baseline in 
all dose levels & 
genotypes 
compared to 
placebo. 
NA 117 
 (1 study) 
Low 
(1,3) 
Data 
analysed 
via a 
MMRM. 
Results can 
averaged 
from week 
2 and week 
4 
FEV1 (% 
predicted): 
absolute 
change from 
baseline 
One study found a statistically 
significant improvement in absolute 
change in FEV1 % predicted at the 
dose of 120 mg twice daily versus 
NA 12  
(1 study) 
Low 
(1,3) 
A second 
study (n = 
117) found 
a 
statistically 
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Follow-up: 2 
weeks 
placebo, MD 10.00 % predicted (95% 
CI 3.04 to 16.96). 
significant 
improvem
ent in the 
absolute 
change in 
FEV1 (L) at 
all dose 
levels and 
genotypes 
when 
compared 
to placebo. 
Adverse 
events 
 
Follow-up: 2 
to 4 weeks 
There was no significant difference in 
the number of participants 
experiencing at least 1 adverse event 
between the intervention and 
placebo at any dose or for any 
genotype. There was also no 
statistical difference versus placebo 
relating to the severity of adverse 
events across all doses and genotype 
groups. 
NA 129  
(2 
studies) 
Low 
(1,3) 
Longer-
term data 
in a larger 
number of 
participant
s will be 
very 
important 
for adverse 
event data. 
Time to first 
pulmonary 
exacerbatio
n 
 
Follow-up: 
NA 
Outcome not reported NA 1 study (n 
= 117) did 
report no 
difference 
in the 
number of 
courses of 
antibiotics 
required or 
the 
number of 
pulmonary 
exacerbati
ons 
between 
groups at 
all dose 
levels and 
genotypes. 
 CFQ-R: Cystic Fibrosis Questionnaire-Revised; CI: confidence interval; FEV1: forced expiratory 
volume at 1 second; MD: mean difference; MF: minimal function; MMRM: mixed model for 
repeated measures; NA: not applicable. 
1. Downgraded once due to risk of bias: unclear methodological information reported regarding 
blinding of outcome assessors and potentially selective reporting of outcomes 
2. Downgraded once due to imprecision: no data available and only measured in a small number 
of participants over a short timescale. 
3: Downgraded once due to indirectness / lack of applicability: Data doesn't include children and 
those with more severe disease. Also short-term data only. 
Table 23: Summary of findings - Triple combination therapy (VX-659-tezacaftor-ivacaftor/VX-561) 
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VX-445-tezacaftor-ivacaftor 
Outcomes Illustrative comparative 
risks (95% CI) 
Relativ
e effect 
(95% 
CI) 
No of 
Participant
s 
(studies) 
Quality 
of the 
evidenc
e 
(GRADE) 
Comments 
Assumed 
risk 
Correspondin
g risk 
Triple 
placebo or 
placebo-
tezacaftor
-ivacaftor 
VX-659 plus 
tezacaftor 
plus ivacaftor 
or VX-561 
Survival 
 
Follow-up: 4 
weeks 
No deaths 
reported 
No deaths 
reported 
NA 123 
(1 study) 
Low 
(1,2)  
 
Quality of 
life: total 
score 
 
Follow-up: 
NA 
Outcome not reported NA  
Quality of 
life: CFQ-R 
respiratory 
domain: 
absolute 
change from 
baseline 
 
Follow-up: 4 
weeks 
A statistically significant 
improvement in the CFQ-R 
respiratory domain was 
observed versus placebo 
across all dose levels and 
both genotypes. 
NA 123 
(1 study) 
Low  
(1,3) 
A higher 
score 
indicates a 
better 
outcome. 
FEV1 (% 
predicted): 
relative 
change from 
baseline 
 
Follow-up: 4 
weeks 
A statistically significant 
improvement in FEV1 
relative change from 
baseline in favour of the 
intervention was observed 
versus placebo across all 
dose levels and genotypes. 
NA 123 
(1 study) 
Low 
(1,3) 
 
FEV1 (% 
predicted): 
absolute 
change from 
baseline 
 
Follow-up: 
NA 
 
 
 
 
 
 
 
 
 
 
Outcome not reported NA NA NA 1 study (n = 
123) reported 
a statistically 
significant 
improvement 
in the 
absolute 
change from 
baseline in 
FEV1 (L) 
favouring the 
intervention 
across all 
dose levels 
and 
genotypes 
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Adverse 
events 
 
Follow-up: 4 
weeks 
There was no significant 
difference in the number of 
participants experiencing at 
least 1 adverse event 
between the intervention 
and placebo at any dose or 
for any genotype. There 
was also no statistical 
difference versus placebo 
relating to the severity of 
adverse events across all 
doses and genotype groups. 
NA 123  
(1 study) 
Low 
(1,3) 
Longer-term 
data in a 
larger 
number of 
participants 
will be very 
important for 
adverse 
event data. 
Time to first 
pulmonary 
exacerbatio
n 
 
Follow-up: 
NA 
Outcome not reported. NA 1 study (n = 
123) 
observed no 
difference in 
the number 
of courses of 
antibiotics 
required or 
the number 
of pulmonary 
exacerbation
s between 
groups all 
dose levels 
and 
genotypes. 
CFQ-R: Cystic Fibrosis Questionnaire-Revised; CI: confidence interval; FEV1: forced expiratory 
volume at one second; MD: mean difference; MF: minimal function: NA: not applicable. 
1. Downgraded once due to risk of bias: unclear methodological information reported regarding 
blinding of outcome assessors and potentially selective reporting of outcomes. 
2. Downgraded once due to imprecision: no data available and only measured in a small number 
of participants over a short timescale. 
3: Downgraded once due to indirectness / lack of applicability: Data doesn't include children and 
those with more severe disease. Also short-term data only. 
Table 24: Summary of findings- Triple combination therapy (VX-445-tezacaftor-ivacaftor/VX-561) 
GRADE levels of evidence (as stated in the above tables): 
High quality: Further research is very unlikely to change our confidence in the estimate of 
effect. 
Moderate quality: Further research is likely to have an important impact on our confidence 
in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence 
in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
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Table 25: Larger version of risk of bias assessment table for study of reported outcomes 
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The James Lind Alliance’s cystic fibrosis PSP’s top 10 research priorities 
1. Finding ways to simplify the burden of treatment which people with CF have. 
2. Ways to improve relief of gastrointestinal issues such as abdominal pain, nausea, 
bloating. 
3. Best treatment & when to start it for non-tuberculous mycobacterium infections in 
CF. 
4. Identifying the best ways of preventing, delaying or slowing the progression of lung 
disease in the early life of those with CF. 
5. Explore potential ways of preventing CF related diabetes. 
6. Ways of motivating and supporting adherence to treatment. 
7. Is it possible for exercise to replace chest physiotherapy? 
8. Antibiotic regimes- what combinations and doses should be used during 
exacerbations and should they be rotated? 
9. Ways to reduce problems associated with antibiotics such as resistance, adverse 
effects. 
10. Look for the best way of eradicating Pseudomonas aeruginosa. 
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Poster for review of outcomes 
Presented at European Cystic Fibrosis Conference, Liverpool 2019. 
 
Clinical trials in pre-school children with cystic fibrosis; are we measuring the right 
outcomes?
Jared Murphy1, Ian P Sinha1,2, Alan R Smyth3, Nikki Jahnke
4, Tracey Remmington4, Kevin W 
Southern1,2
Conducting clinical trials in pre-school children with CF (pscwCF) is a 
challenge and there is no formal consensus on the best outcomes to 
measure and report in this age group.
Core outcome sets exist to provide guidance on the minimum 
standard required of clinical trials for which outcomes they should 
measure and report. Providing at least this minimum amount of 
appropriate information could have the effect of reducing 
heterogeneity of trials, allowing easier, and higher quality data 
synthesis for systematic review and decision making. The first step 
towards creating a core outcome set is to assess the current state of 
outcome reporting in pscwCF.
Aim: To record and characterise outcomes reported in trials of 
interventions for 0-5 year olds with CF. 
We identified all Cochrane systematic reviews examining interventions 
for pscwCF. From these, we identified RCTs that exclusively enrolled 
pscwCF. We recorded and classified all outcomes mentioned in the 
protocol (where available), methods and results of each eligible 
systematic review and RCT into two theme sets; one set developed by 
the research team reflecting outcomes listed in the systematic 
reviews: Airway, Microbiology, Extra-thoracic disease, Patient/parent 
reported, Nutrition and Other; and the second set consistent with the 
Core Outcome Measures in Effectiveness Trials (COMET) initiative: 
Death, Physiological/clinical, Life impact, Resource use, Adverse 
events.
Despite a wide search, only ten eligible trials were identified, six had
significant quality issues (high risk of bias). This reflects the challenge
of research in pscwCF; highlighted by the large number of outcomes
measured. The Majority of outcomes identified were classified as
surrogate biomarkers of short term physiological status, with FEV1
alone (a measure known to have little value in pre-school children)
being reported in 5 different RCTs. There was a lack of pragmatic,
longer term outcomes, more reflective of the lived experience of CF
families. The pre-school years are vital for the future health of people
with CF and the lack of comparative effectiveness research in pscwCF
is disappointing.
Further, more comprehensive publications of this work will likely
present the total number of outcomes reported across the protocols,
methodologies and results of all included Cochrane systematic reviews
and RCTs. This work paves the way for further work toward creation of
a core outcome set. This will require engagement with multiple
stakeholders such as patients, families, clinicians and commissioners,
and is commonly performed by means of a Delphi study.
A clear core outcome set would be a useful step for facilitating high 
quality research in this age group. 
We identified 29 systematic reviews of relevant interventions for 
pscwCF. Those reviews contained 295 trials, 10 were eligible for 
inclusion in this study.  For 6/10 trials the risk of bias was high (unclear 
in 3, low in one). 
Methods
Background
Conclusion
1: Department of Women’s and Children’s Health, University of Liverpool, 2: Alder Hey Children’s Hospital, Liverpool; 3: Division of Child Health, Obstetrics and Gynaecology, 
University of Nottingham; 4: Cochrane Cystic Fibrosis & Genetic Disorders group, University of Liverpool.
Discussion
Results
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Figure 1- Number of different outcomes, classified according to themes identified 
from RCTs 
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Figure 2- Number of different outcomes, classified according to themes identified by 
the COMET Initiative 
Number of outcomes
65 different outcomes were reported 127 different times.
The most common themes for the study team’s theme set were 
‘Other’ (n=19) and ‘Airway’ (n=17). The most common COMET theme 
was ‘Physiological/clinical’ (n=54).
The least commonly reported of the study team’s themes was 
‘Patient/parent reported’ (n=3). The most similar theme in the COMET 
set, ‘Life impact’, was reported 7 times.
See figures 1 and 2 for a breakdown of how many outcomes are 
reported under each theme.
Table 1 – Examples of outcomes reported in included RCTs, and how they were classified according to both the CF 
research team’s themes and the COMET initiative themes.
Example of different 
outcomes
Respective research team CF
theme for this outcome
Respective COMET theme 
for this outcome
FEF 25-75 Airway Physiological/clinical
Number of oesophageal reflux 
episodes
Extra-thoracic disease Physiological/clinical
Quality of life Patient/parent reported Life impact
Anthropometric measure of 
nutrition/growth
Nutrition Physiological/clinical
Number of exacerbations Microbiology Physiological/clinical
Duration of hospital stay Other Resource use
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Clinical trials in pre-school children with cystic fibrosis; are we measuring the right outcomes?
Jared Murphy
1
, Ian P Sinha
1,2
, Alan R Smyth
3
, Nikki Jahnke
4
, Tracey Remmington
4
, Kevin W Southern
1,2
1: Department of Women’s and Children’s Health, University of Liverpool, 2: Alder Hey Children’s Hospital, Liverpool; 3: Division of Child 
Health, Obstetrics and Gynaecology, University of Nottingham; 4: Cochrane Cystic Fibrosis & Genetic Disorders group, University of 
Liverpool.
Conducting clinical trials in pre-school children with CF (pscwCF) is a challenge.
There is no formal consensus on the best outcomes to measure and report in this age group.
Core outcome sets provide guidance on the minimum standard required of clinical trials for which 
outcomes they should measure and report. Providing at least this minimum information could reduce 
heterogeneity, allowing easier, and higher quality data synthesis for systematic review and decision 
making.
The first step towards creating a core outcome set is to assess the current state of outcome reporting in 
pscwCF.
Background
Methods
1. We identified all Cochrane systematic reviews examining interventions for pscwCF.
2. From these, we identified RCTs that exclusively enrolled pscwCF.
3. We recorded and classified all outcomes mentioned in the protocol (where available), methods and 
results of each eligible systematic review and RCT into two theme sets; one set developed by the research 
team reflecting outcomes listed in the systematic reviews (table 1, below) and the second set consistent 
with the Core Outcome Measures in Effectiveness Trials (COMET) initiative (table 2, below):
Table 1: Cystic Fibrosis themes
Airway
Microbiology
Extra-thoracic disease
Patient/parent reported outcomes
Nutrition
Other
Table 2: COMET themes
Death
Physiological/clinical
Life impact
Resource use
Adverse events
Table 3 – Examples of outcomes reported in included RCTs, and 
how they were classified according to both the CF research team’s 
themes and the COMET initiative themes.
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Outcomes listed in RCTs 
Methods 
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Results stage 
 
